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1 Zusammenfassung 
Das angeborene Immunsystem stellt die erste Abwehrlinie gegen Infektionen und Krebs dar 
und ist daher maßgeblich am Erfolg von Tumor-spezifischen Immunantworten beteiligt. Ein 
kritischer Aspekt der Entstehung von Melanom ist die Fähigkeit, der Zerstörung durch das 
eigene Immunsystem zu entgehen. An diesem Punkt setzen moderne Therapien an, indem 
sie die Inhibition des Immunsystems auflösen, wie durch den erfolgreichen Einsatz von 
Checkpoint Inhibitoren demonstriert wurde. In vielen Patienten häufen sich jedoch 
Mutationen in Genen für die Antigenpräsentierung, was dazu führt, dass diese Patienten 
nicht auf T-zell vermittelte Immunantworten reagieren. In diesem Fall könnte die 
therapeutische Manipulation angeborener Immunantworten eine effektive Methode zur 
Vorbeugung der Tumorprogression und Metastasierung darstellen. In dieser Studie wird die 
Wirkung von zwei Immunzellen des angeborenen Immunsystems, slan+ Monozyten (slanMo) 
und natürlichen Killer (NK) Zellen, gegenüber  Melanom untersucht. Außerdem wird deren 
Aktivierung durch R848 analysiert, einem synthetischen TLR 7/8 Ligand, der aktuell auf 
seine therapeutische Wirksamkeit bei Melanom hin getestet wird. 
Wir werfen die Frage auf, ob slanMo aktiv NK Zellen rekrutieren um angeborene 
Immunreaktionen zu initiieren, welche dann das Tumorwachstum kontrollieren und 
Seneszenz in Melanom Zellen induzieren können. Wir detektieren slanMo wiederholt in 
Melanom befallenem Gewebe, jedoch nur sporadisch in gesunder Haut. Aggressive Formen 
von Melanom waren durch eine geringere Anzahl infiltrierender slanMo gekennzeichnet, die 
außerdem mit der Infiltration von NK Zellen korrelierten. Um zu hinterfragen, ob die 
Korrelation der slanMo und NK Zell Infiltration auf einem zusammenhängenden 
Migrationsmechanismus beruht, untersuchten wir die Chemokin Sekretion von slanMo. In 
vitro Kultivierung von slanMo führte zur Sekretion von verschiedenen Chemokinen wie zum 
Beispiel IL-8/CXCL8, was zusätzlich durch Zugabe von R848 erhöht wurde. Konditioniertes 
Medium von stimulierten slanMo induzierte NK Zell chemotaxis und führte zur herunter 
Regulierung der IL-8 Rezeptoren CXCR1 und CXCR2 auf NK Zellen, was auf eine 
Beteiligung der Rezeptoren hindeutet. Neutralisierungsexperimente identifizierten IL-8 als 
das relevante Chemokin in slanMo CM. Um den Einfluss der slanMo/NK Zell 
Wechselwirkung auf Melanom Zellen zu untersuchen, übertrugen wir Überstände von R848-
stimulierten slanMo/NK Zell Ko-Kulturen auf Melanom Zellen, was das Wachstum der 
Melanom Zellen stark einschränkte. R848-stimulierte slanMo/NK Zell Ko-Kulturen enthielten 
hohe Mengen an TNF-α und IFN-γ, die nicht erreicht werden konnten wenn NK Zellen mit 
CD14+ Monozyten oder slanMo mit T Zellen inkubiert wurden. Experimente mit 
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neutralisierenden Antikörpern demonstrierten die Seneszenz induzierende Funktion von 
TNF-α und IFN-γ in slanMo/NK Zell Überständen, welche durch reduzierte Proliferation, 
gesteigerte Expression von Seneszenz-assoziierter β-Galactosidase und p21, und dem 
Auftreten eines Seneszenz-assoziierten Sekretorischen Phänotyps in Tumor Zellen 
gekennzeichnet ist.  
Zusammenfassend wurde hier das Potenzial der angeborenen Immunität in Bezug auf die 
Generierung einer Seneszenz-induzierenden Umgebung, ermöglicht durch Stimulierung mit 
TLR Liganden, untersucht. Diese Studie bietet Einsichten in den therapeutischen 
Wirkmechanismus  von TLR Liganden, wie zum Beispiel dem TLR 7/8 Liganden Imiquimod, 
der zur topischen Behandlung von Melanom eingesetzt wird. In diesem Zusammenhang 
sprechen unsere Ergebnisse für eine optimale Stimulierung von slanMo im Tumor, was dann 
durch Rekrutierung von NK Zellen zu Seneszenz in Melanom Zellen führen könnte. 
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2 Summary 
Innate immune cells represent the first line of defense against infections and cancer and 
therefore play a pivotal role in determining the fate of anti-tumor immune responses. As a 
critical aspect of melanoma biology is represented by the ability to evade immune 
destruction, modern therapies can benefit from breaking immune suppression, as 
demonstrated by checkpoint inhibitor therapy. However, many patients acquire defects in 
antigen presentation and thereby remain unresponsive to T cell mediated immune clearance. 
For those patients, therapies enabling innate immune responses might prove to be effective 
in preventing cancer progression and metastasis. Therefore, this study investigated the anti-
melanoma effects of two innate immune cell types, slan+ monocytes (slanMo) and natural 
killer (NK) cells, in combination with stimulation by R848, a synthetic TLR 7/8 ligand for 
topical application that is currently investigated regarding therapeutic efficacy in melanoma. 
Here, we addressed the question whether slanMo actively recruit NK cells in order to initiate 
an innate immune response that limits tumor growth and induces senescence in melanoma 
cells. We showed that slanMo are frequently detected in melanoma tissue, but rarely in 
healthy skin. More invasive forms of melanoma exhibited reduced numbers of infiltrating 
slanMo that were accompanied by correlating numbers of NK cells. To elucidate whether the 
correlating infiltration patterns represent a connected migration mechanism, we investigated 
chemokine production by slanMo. In vitro culture of slanMo resulted in the secretion of 
various chemokines such as IL-8/CXCL8, which was further increased by stimulation with 
R848. Stimulated slanMo conditioned medium (slanMo CM) induced chemotaxis of NK cells 
and led to the downregulation of the IL-8 receptors CXCR1 and CXCR2 on NK cells, 
indicative of receptor engagement. Neutralization experiments revealed IL-8 as the relevant 
NK cell chemoattractant in slanMo CM. To investigate the influence of the slanMo/NK cell 
crosstalk on melanoma cells, we transferred supernatants from R848-stimulated slanMo/NK 
cell co-cultures to melanoma cells, resulting in strongly attenuated cell growth. We found that 
R848-stimulated slanMo/NK cell co-culture CM contained high levels of TNF-α and IFN-γ, not 
reached when NK cells were cultured with CD14+ monocytes or slanMo were cultured with T 
cells. Neutralization experiments revealed that TNF-α and IFN-γ present in slanMo/NK cell 
co-culture CM induced senescence in melanoma cells as indicated by reduced proliferation, 
increased senescence-associated β-Galactosidase expression, p21 upregulation, and 
induction of a senescence-associated secretory phenotype (SASP) in the tumor cells. 
Taken together, this study describes the potential of innate immunity to generate a 
senescence inducing microenvironment after stimulation with TLR ligands. We provide 
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insight into the therapeutical mechanism of TLR ligands such as the TLR 7/8 ligand 
Imiquimod for topical melanoma therapy. Accordingly, our results argue for increased NK cell 
recruitment as a foundation for eliciting slanMo/NK cell crosstalk induced melanoma cell 
senescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
  
3 Introduction 
3.1 The Immune System 
The immune system is responsible for defending the body against foreign dangers such as 
bacteria, viruses, fungi, or parasites. Naturally, it is a race between the pathogen and the 
host’s immune system, where each side developes strategies to evade destruction by the 
opponent. To protect the organism against damage, the immune system possesses a variety 
of specialized cells that can be roughly divided into two arms – innate immune cells and 
adaptive immune cells. The major discriminating factor is that innate immunity offers 
immediate protection against pathogens in the range of minutes to hours, whereas adaptive 
immunity requires clonal selection and maturation, delaying adaptive immune responses to a 
magnitude of days and weeks. Together, both arms of the immune system provide powerful 
and long lasting immunity, which can again be divided into two parts: (1) Cellular interactions 
between immune cells and pathogens resulting in direct killing, and (2) the secretion of 
soluble factors and antibodies recognizing pathogenic motifs and thereby facilitating 
neutralization and clearance of infections. As a result, immune responses need to be subject 
to thorough regulation, as misguided or overshooting reactions pose a threat to the host 
organism. Besides danger-associated functions, the immune system is also involved in 
tissue homeostasis, i.e. through removing apoptotic cells and supporting tissue regeneration 
after injury. 
3.1.1 Innate Immunity 
The innate immune system is the first line of defense against pathogens. Innate immune 
cells are therefore readily present and active within tissues lining the body surface, which are 
mainly the skin and the mucosal system. Human white blood cells, also called leukocytes, 
generally originate from the bone marrow. In human blood, the major innate leukocyte 
populations are:  
Neutrophils 
Neutrophils are the most abundant leukocyte population in the blood and often mediate fast, 
but short-lived reactions. Morphologically, they can be identified by a segmented nucleus, 
which led to the alternative name of polymorphonuclear leukocytes. Already at steady state, 
neutrophils possess cytoplasmic granules filled with lytic enzymes and other anti-microbial 
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agents such as defensins, which allow them to immediately target invading pathogens. The 
major focus of neutrophils, however, lies in the phagocytosis of pathogens. 
Mononuclear Phagocytes 
Human Monocytes can be divided in three subgroups identified by the expression of the 
surface markers CD14 and CD16 (Fcγ Receptor III): (1) classical monocytes are 
CD14+CD16- ; (2) intermediate monocytes are CD14+CD16+ ; and (3) non-classical 
monocytes are CD14-/dimCD16+ 1. Non-classical monocytes can further be subdivided based 
on expression of the carbohydrate modification 6-sulfo LAcNAc (slan) on PSGL-1 2. Those 
slan+ monocytes were termed slanMo and will be discussed together with NK cells in section 
3.2. After migration into tissues, monocytes can mature and become macrophages. In 
addition to monocyte-derived macrophages, organs also harbor specialized tissue resident 
macrophages that function in tissue homeostasis and local immune reactions, such as 
microglia in the brain or alveolar Kupffer cells 3, 4. Similar to neutrophils, monocytes and 
macrophages are potent phagocytes and often mediate long-term clearance as a 
supplement to short-lived neutrophil reactions. In addition, secretion of cytokines such as 
TNF-α, IL-6 and IL-8, allows mononuclear phagocytes to influence local immune reactions 
and recruit subsequent waves of immune cells, termed acute phase response 5.  
In the murine system, monocytes consist of Ly6Chigh and Ly6Clow monocytes, being 
homologous to human classical and non-classical monocytes, respectively. Ly6Clow 
monocytes are also called patrolling monocytes, which stems from observations of those 
cells crawling along the endothelium, a phenotype they share with their human counterpart 6. 
However, it is still unclear whether a murine homolog for human slanMo exists, since no 
carbohydrate modification comparable to slan is reported to be present on murine monocytes 
up to date. 
Dendritic cells (DCs) 
Dendritic cells (DCs) are specialized antigen-presenting cells (APCs). In that way, they 
function as a critical relay between the innate and adaptive immune response. APCs, in 
contrast to MHC-I associated self-peptide display on all cells, can present external molecules 
to naïve T cells and thereby initiate adaptive immune responses. Conventional DCs (cDCs) 
are the most abundant DC subset in tissues and lymphoid organs and constantly monitor the 
surrounding environment for exogenous particles, a behavior that is facilitated by formation 
of long protrusions, so-called dendrites. Plasmacytoid dendritic cells (pDCs) represent 
another DC subset in blood and tissue, which are mostly involved in Type I Interferon-
mediated anti-viral responses. 
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Mast cells, Basophils, and Eosinophils 
Mast cells are absent in the circulation, but can be found in tissues where they impact local 
immune reactions, most commonly allergic reactions. Similar to neutrophils, basophils and 
eosinophils are blood granulocytes characterized by accumulation of lytic granules. 
Natural killer (NK) cells 
NK cells belong to the lymphocytic system as they together with T and B cells originate from 
the common lymphoid precursor. NK cells share many functions with T cells but lack the 
antigen receptor machinery. Therefore, NK cells also count as innate immune cells and will 
be discussed in more detail in section 3.2, as they are an integral part of this thesis. 
3.1.2 Innate immune recognition 
The innate immune system is specialized in directly responding to threats without requiring 
prolonged activation periods. This is enabled by receptors recognizing certain pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs). PAMPs are proteins, lipids, or DNA, directly originating from the pathogen, 
whereas DAMPS are often molecules that become exposed after tissue damage or 
apoptosis of host cells, such as nuclear or stress-induced proteins. The major pattern 
recognition receptors (PRRs) are membrane-bound Toll-like receptors (TLRs), C-type lectin-
like receptors (CLRs), and scavenger receptors, as well as cytosolic NOD-like receptors 
(NLRs) and RIG-like receptors (RLRs) 7. TLRs are special in the way that the receptors can 
be present on the cell surface as well as on endosomes. In humans, 9 TLRs are known, of 
which TLR3, 7, 8, 9 appear exclusively on endosomal membranes 8, 9, 10. Several receptor-
ligand pairs have been described to date, i.e. bacterial cell wall-derived lipopolysaccharid 
(LPS) can trigger the common adapter protein MyD88 via TLR4 signaling and thereby 
mediate NF-κB activation, leading to the transcription of NF-κB target genes such as the 
cytokines TNF-α, IL-12, IL-1, IL-6, and chemokines such as CCL2 and CXCL8 (IL-8) 11. 
Endosomal TLRs recognize different polynucleotide configurations, i.e. single stranded RNA 
(ssRNA) binding to TLR7 and TLR8 to induce NF-κB signaling 12. 
An important aspect of all those receptors is that they are germ-line encoded and therefore 
are not dependent on antigen-specific maturation. On the other hand, this also represents a 
major caveat of innate immunity, namely the inability to react to changes outside the inherent 
repertoire, i.e. when bacteria acquire mutations that alter protein structure or lipid 
modifications. 
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3.1.3 Adaptive Immunity 
The common lymphocyte progenitor gives rise to T cells, B cells, and NK cells. Among 
lymphocytes, T and B cells orchestrate long-lasting immune responses based on highly 
variable antigen receptors that are generated through gene rearrangement. Even though 
recent reports also demonstrate certain memory functions for NK cells, the basic concept of 
immunological memory refers to T and B cell immunity. 
As common to all blood cells, lymphocytes are generated in the bone marrow. However T 
and B cells are unique in that they require specialized lymphoid organs for their 
development. B cells remain in the bone marrow, whereas T cells migrate to the thymus for 
their final maturation to take place. In general, both T and B cells undergo certain selection 
processes to assure that only clones with a functional, yet not excessively strong binding 
antigen receptor are released to the periphery. This process is called central tolerance and 
involves several steps: (1) Pre-antigen receptor expression; only cells that express functional 
pre-receptors, which are composed of only one of the final receptor chains, receive survival 
signals and evade apoptotic cell death. (2) Antigen receptor expression; at this stage, T and 
B cells rearrange the genes for the second antigen-receptor chain, called V(D)J 
recombination. Random combination of V(D)J rearranged single chains generates a 
theoretical diversity of ~1011 B cell receptors (BCR) and ~1016 T cell receptors (TCR). (3) 
Positive selection; T and B cells that express functional antigen-receptors are selected and 
proliferate to increase the pool of functional cells. (4) Negative selection; In order to prevent 
immune reactions against own tissues, so called autoimmune reactions, the pool of 
functional T and B cells is cleared of clones expressing highly reactive antigen-receptors. 
Those clones that survive both positive and negative selection advance and migrate into the 
periphery. However, it is not rare that autoreactive T or B cells escape central tolerance. 
Therefore, it is also important to constantly control immune activity in the periphery. 
Peripheral tolerance is mostly maintained by T regulatory cells (T regs) that are supposed to 
regulate chronic or exacerbated immune responses through sercretion of inhibitory cytokines 
such as IL-10. Additionally, overly active T cells in the periphery can enter a state of anergy, 
which renders them unresponsive. 
As mentioned before, adaptive immune responses require an additional priming phase in the 
magnitude of days. The high diversity of possible TCRs and BCRs increases the likelihood of 
reactive T and B cells being present virtually at any time and against any pathogen. 
However, the need for high diversity also reduces the actual number of reactive cells and 
therefore, after recognizing its cognate antigen, the lymphocyte first enters several rounds of 
proliferation and affinity maturation, a process where the specificity of the variable region is 
further fine-tuned for optimal binding of the exogenous ligands. This priming usually takes 
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place in secondary lymphoid organs such as lymph nodes and the spleen, where APCs 
immigrate to present tissue antigens to T cells and to provide co-stimulatory signals. T cells 
consist of two major subsets, CD4 and CD8 T cells, and the major discriminator is selective 
binding to peptide-MHC-II and peptide-MHC-I complexes, respectively. However, the subsets 
also differ functionally. Whereas CD4 T cells are classically viewed as stimulatory cells, 
characterized by secreting cytokines and activating B cells, earning them the name T helper 
(Th) cell, CD8 T cells are also called cytotoxic T cells due to their established cytotoxic 
properties and direct killing of target cells through perforin and granzyme production.  
B cells also undergo their priming phase in lymph nodes, where APCs, Th cells, and B cells 
come together. In this environment, B cells prepare for high scale production of a soluble 
form of the BCR, called Immunoglobulin (IgG), or antibody. Antibodies can neutralize target 
pathogens or toxins by opsonization of the targets. Additionally, opsonized pathogens are 
easy targets for cells carrying special receptors recognizing the constant antibody region. A 
major hallmark of adaptive immunity are memory responses, meaning that both T and B cells 
can develop long-lived subpopulations that retain epitope specificity of the first antigen 
encounter and can mount immediate responses after re-encounter of the same pathogen. In 
the classical case of vaccination, memory B cells maintain long-lasting immunity through 
constant secretion of pathogen-specific antibodies that prevent subsequent infections. 
Other rare immune cell populations complete the lymphocytic system. Those include NK T 
cells, innate lymphoid cells (ILCs), and γδ T cells 13, 14, 15. γδ T cells share the development 
with conventional αβ T cells. However, γδ TCR rearrangement generates far less variability 
and γδ TCRs rather resemble PRRs, which is why they are considered part of innate 
immunity. Of note, also CD4 Th cells are further subdivided into different subsets, most 
prominently the Th1 and Th2 subsets, but over the recent years more subsets were added, 
i.e. Th17 cells, which are suggested to possess high inflammatory driving potential, in 
particular in skin diseases such as psoriasis 16. 
3.1.4 Trafficking and tissue homing of immune cells 
After their generation in the bone marrow, immune cells enter the blood stream, allowing 
them to reach virtually all vasculated tissues. Therefore, the immune cell composition in the 
blood that can be monitored at any given point is the combined result of both the supply of 
newly generated cells (influx), as well as the egress into tissues (efflux). Extravasation, which 
describes the exit from the blood stream, generally involves different steps called the 
leukocyte adhesion cascade 17. 
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Leukocyte transmigration 
The first steps of emigration from the blood stream are defined by interactions with 
endothelial cells. These interactions involve different adhesion receptors of varying affinity. 
The interactions are gradually increasing in adhesion strength until the cell remains 
stationary on the vessel wall. PSGL-1 on leukocytes mediates the interaction with the 
endothelium by binding to selectins, in particular E- and P-selectin, expressed on inflamed 
endothelial cells as well as L-selectin expressed on other leukocytes 18. In addition, integrins 
and their ligands also support rolling, i.e. very late antigen 4 (VLA4; α4β1-integrin) and 
lymphocyte function-associated antigen 1 (LFA-1; α1β2-integrin), expressed on lymphocytes, 
can engage vascular cell-adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 
1 (ICAM1), respectively, together mediating firm adhesion and thereby reducing rolling speed 
19. During the rolling process, leukocytes receive signals through their interactions with the 
endothelium, which in turn transform integrins to higher affinity conformations via inside-out 
signaling, finally rendering the leukocytes stationary. Those activating signals include integrin 
signaling via VLA4 and LFA-1. However, the most efficient inside-out signaling is transmitted 
by g-protein coupled receptor (GPCR)-mediated chemokine signaling relying on ectopic 
luminal expression of chemokine ligands. Arrested cells then receive outside-in signals 
through integrins to further strengthen adhesion to the vasculature and prevent detachment 
20. After firm attachment, leukocytes prepare for transmigration through the endothelial layer. 
Monocytes have been observed to crawl along the vasculature in search for optimal 
transmigration areas. The transmigration process is initiated by binding of leukocyte integrins 
to their ligands on endothelial cells together with a local accumulation of ICAM1 and VCAM1, 
strongly facilitating transmigration 21, 22. Crossing the endothelial layer can occur in two ways, 
either between neighboring endothelial cells (paracellular) or directly through individual 
endothelial cells (transcellular). In general, this whole cascade is predominantly taking place 
in inflamed areas, where the local environment activates the endothelium to enable 
attachment against shear stress. 
The chemokine system 
Circulating immune cells can enter tissues by firm adhesion and subsequent transmigration. 
However, the concept of homeostatic tissue homing is not well understood and mostly 
investigated regarding certain immune cell populations such as monocytes or neutrophils. 
Understandably, in homeostasis, only cells expressing respective adhesion molecules are 
able to extravasate. Under inflammatory conditions, tissues experience strongly increased 
leukocyte influx, which is mostly mediated by changes in the endothelium. In those settings, 
chemokines are involved in recruiting and guiding particular leukocyte subsets to their 
destination. This is mediated by chemokine receptor – chemokine binding and subsequent 
11 
 
  
signaling. There are two major groups of chemokines, the C-X-C chemokines and the CC 
chemokines, referring to a specific sequence motif shared by all chemokines in the group. 
Only two sets of chemokines are unique and cannot be added to the two groups, namely the 
C chemokines XCL1 and XCL2, and the CX3C chemokine fractalkine (CX3CL1). The 
specificity of chemokine receptors is heterogeneous, even though certain exclusive receptor 
– ligand pairs exist, i.e. C-X-C Chemokine receptor 4 (CXCR4) – C-X-C chemokine ligand 12 
(CXCL12; also called stromal-derived-factor 1 (SDF-1)) (Fig. 3.1) 23.  
Chemokine receptors transmit their signals exclusively via GPCRs. In general, triggering 
chemokine GPCRs relays signals via phospholipase Cβ2 (PLC2) directed calcium influx and 
other pathways, such as the mitogen-activated protein kinase (MAPK) pathway 20. This 
affects various morphological and migratory features, including changes in adhesion 
molecule avidity, actin rearrangement and polarization, production of lysosomal enzymes, 
and increased locomotive behavior. 
Chemokine – chemokine receptor interactions are important in many physiological and 
inflammatory settings. CCR7 is expressed on T cells, B cells, and certain dendritic cells and 
binds to CCL19 and CCL21 24, 25. In secondary lymphoid organs (SLO) like the spleen or 
lymph nodes, CCR7 is pivotal in guiding T cells to the respective T cell areas, thereby also 
enabling the formation of SLO architectural structures, for which T cells constitute a major 
part 26, 27. CCR7-/- mice display strongly altered SLO morphology, which is owed to 
malfunction in DC and T cell recruitment, in turn disrupting the initiation of the entire adaptive 
immune response. Interestingly, CCR7-/- T cells manage to reach SLOs, are however then 
trapped and unable to migrate to sub-organ structures 26. 
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Figure 3.1 – The Chemokine system. Chemokine receptors are either specific for a single 
chemokine or are heterogenous regarding different chemokine binding ligands. Similarly, chemokine 
ligand – chemokine receptor pairs can also be specific for one combination or a single chemokine can 
bind various receptors. Adapted from Proudfoot et al., 2002 28. 
3.1.5 Tumor Immunology 
Tumor immunology describes the interactions between transformed cells and the immune 
system. It is established for a long time that innate and adaptive immunity can recognize and 
eliminate tumor cells. In this line of thought, it is also conceivable that many initial tumor and 
metastasis formations are stopped in its tracks by the immune system, which acts as a 
homeostatic malignancy sensor in the cancer immunosurveillance model.  
The concept of tumor immunology expands the immune surveillance model and is typically 
divided in three stages: Elimination, Equilibrium, and Escape – the three E’s (Fig. 3.2) 29, 30. 
3.1.5.1 Elimination 
Many innate immune cell subsets are readily present in tissues and therefore form the 
majority of sentinel cells. The process of malignant transformation is often accompanied by 
severe changes in the affected cells. Transformed cells are known to secrete or present 
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different stress-associated molecules. Several stress-induced ligands can bind to activating 
NK cell receptors, which will be a topic in 3.2.2.1. Soluble factors are secreted or released 
after necrotic tumor cell death. An example is the high mobility group box 1 protein (HMGB1), 
a protein usually localized in the nucleus, which is released by dying tumor cells 31, 32. 
Importantly, HMGB1 can activate monocytes and trigger increased TNF-α production, a 
process believed to function via binding to the receptor for advanced glycation enproducts 
(RAGE) and TLR receptors 31, 33. 
3.1.5.2 Equilibrium 
Tumor clones initially spared by immune cell elimination often enter a state in which they 
adapt their immunogenicity by mutations in the antigen presentation machinery or even in 
specific T cell antigens. In the equilibrium phase, tumor cells are forced into a kind of 
dormant state by cytotoxic T cells, which eliminate proliferating tumor cells. In fact, studies in 
a tumor mouse model revealed that T cells effectively regulate outgrowth of immunogenic 
tumor variants, since ablation of T cells in this model led to immediate tumor progression 34. 
This effect was further dependent on IFN-γ, yet independent of the innate immune system, 
since depletion of NK cells had no effect on tumor regression. The low proliferative state 
facilitates to remain undetected in ongoing immune responses and allows to acquire 
mutations in order to reduce immunogenicity.  
3.1.5.3 Escape 
The escape phase describes the recurrent outgrowth of single, low level immunogenic tumor 
cells. Tumor cells employ different mechanisms to evade destruction by the immune system: 
Individual tumor clones can alter their antigen presentation in a way to prevent destruction by 
T cells and other cytotoxic cells. Specifically, mutation or loss of β2-Microglobulin (β2m) or 
defects in the IFN-γ signaling pathway (i.e. targeting the IFNGR1 or the JAK1/2 and STAT1 
molecules) render T cell mediated immunity ineffective 30. On the other hand, tumor cells 
often modulate the entire microenvironment in order to generate an immune suppressive 
environment. This can involve direct secretion of immune inhibitory factors such as TGF-β, 
IL-10, Indoleamine 2,3-deoxygenase (IDO), vascular endothelial growth factor (VEGF), or 
soluble forms of activating ligands like MICA (sMICA), thereby blocking the receptors on NK 
cells 35, 36. More prominently, tumor cells can display the inhibitory surface receptors PD-L1 
and CTLA-4, both binding to B7 family proteins on T cells. In this regard, PD-L1 and CTLA-4 
are considered immune checkpoints and both represent recent targets of novel 
immunotherapeutics, so called checkpoint inhibitors 37. In addition to directly secreting 
immune suppressive cytokines, tumor cells also secrete chemokines to recruit and maintain 
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myeloid-derived suppressor cells (MDSCs) or Tregs that then regulate immune responses 
independently, thereby fostering tumor progression 38, 39. Lastly, other tumor cell intrinsic 
mechanisms rely on resisting immune-mediated killing mechanisms by upregulation of anti-
apoptotic proteins such as Bcl-XL or adapting expression of death receptors (Fas ligand, 
TNF-related apoptosis-inducing ligand (TRAIL)) 30. 
 
Figure 3.2 – The three E’s. Illustration of the classical cancer immunoediting concept. Transformed 
cells express DAMPs that activate the immune system, resulting in initial tumor regression in the 
elimination phase. Some tumor clones acquire a low immunogenic state in the equilibrium phase, 
enabling them to escape immune destruction. Adapted from Dunn et. al., 2004 29. 
3.1.6 Tumor infiltrating leukocytes 
According to the concept of tumor immunology, immune cells can mount potent anti-tumor 
responses. However, this is in the first instance reliant on the presence and activity of 
specific immune cell populations in the TME, which is a result of active homing and 
transmigration into solid tumors. Similar to classical inflammatory scenarios, effective anti-
tumor-immunity requires both innate and adaptive immunity to cooperate in initiating and 
maintaining effective immune reactions. Despite their instrumental role in inflammation, the 
role and frequency of monocytes and macrophages in solid tumors is not well understood, 
since most studies focus on cytotoxic T cells as the major targets of checkpoint inhibitor 
therapy. As a consequence, tumors are sometimes classified according to their response 
rates towards checkpoint inhibitor treatment as cold tumors or hot tumors, representing very 
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low or very high T cell infiltration and immunotherapy responsiveness, respectively 40. 
Exclusion of immune cells, in particular effector T cells, can be facilitated by different 
mechanisms, such as modulation of the local chemokine milieu and the endothelial 
composition, together limiting transmigration. Additionally, expression of inhibitory checkpoint 
ligands and the generation of a highly hypoxic environment in the TME often affects the 
viability of immune cells, resulting in reduced proliferative capacity and apoptosis, thereby 
actively reducing the amount of intratumoral immune cells 41. Another aspect that is the topic 
of an ongoing debate is the prognostic value of the intratumoral immune cell composition. 
Naturally, the effectiveness of immune responses heavily relies on the presence and ratios of 
particular immune cell subsets in the TME, since a high proportion of immune cell functions 
are associated with immune regulation and inhibition of excessive immune reactions. Similar 
to classical immune cell recruitment to sites of inflammation, circulating immune cells rely on 
migratory cues that guide their infiltration into the TME. Recently, different methods including 
whole tumor transcriptomic analysis as well as single-cell resolution techniques such as 
single-cell RNA-sequencing, mass cytometry, and in situ staining, were used to decipher the 
immune cell composition for different tumor entities 42, 43, 44. Importantly, correlation of 
immune cell signatures with patient survival and therapy responsiveness allows to infer a 
prognostic value for specific immune cell populations in the TME 45. While the presence of 
cytotoxic T cells and NK cells generally argues for a positive prognosis, it is now clear that 
also the activation status of effector cells, which is regulated by tumor- or immune cell-
derived factors, is pivotal for effective tumor clearance 46, 47. Hence, the presence of immune-
inhibitory MDSCs, Tregs, and inhibitory ligands, which skews T cells towards an exhausted 
phenotype, is associated with a worse outcome, an observation that mirrors the concept of 
tumor escape from immune destruction by immunoediting 48, 49. Nevertheless, it remains 
challenging to allocate specific prognostic values to individual immune cell populations, since 
many immune cell subsets in humans are poorly characterized regarding their marker and 
activation profile in tissues and tumors. Therefore, it is often required to include a broad 
panel of markers to specifically address one cell type, even for single-cell resolution 
techniques. 
The prognostic value of monocytes and macrophages in tumors is still ambigous. For one, 
classical monocytes are repeatedly associated with chronic, tumor-promoting inflammation 50, 
51, 52. In contrast, the subset of patrolling monocytes has been found to exert anti-metastatic 
functions, since knockout mice lacking this particular subset showed a severly increased 
metastatic load 53. Despite a bias towards a negative prognostic value, monocytes and 
macrophages are also reported to posses potent anti-tumor function under certain 
conditions. Macrophages in tissues are often divided into two functional groups; M1 and M2 
polarized macrophages, exerting rather an anti-tumorigenic and pro-tumorigenic role, 
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respectively 54. In the TME, macrophages are further classified as tumor-associated 
macrophages (TAMs), which generally represent a tumor fostering, M2-like phenotype 55. In 
line with the pro-tumorigenic properties of classical monocytes, Franklin et al. demonstrated 
that TAMs originate from CCR2+ classical monocytes 56. 
3.2 Interactions between innate immune cells 
Innate and adaptive immunity often interact to establish and support powerful and long-
lasting immune responses, as described for DCs priming and supporting antigen specific T 
cells. Since certain innate immune cell populations also require stimulation and maturation 
phases, similar synergistic interactions also occur inside the innate immune system. 
3.2.1 Origin and function of slan+ monocytes (slanMo) 
Around 20 years ago, Schäkel and colleagues generated the monoclonal antibody (mAb)    
M-DC8 by immunizing mice with a T cell-, B cell-, and CD14+ monocyte-depleted, HLA-DR+ 
leukocyte fraction 2. It was later discovered that M-DC8 binds to a hitherto unknown 
carbohydrate modification on PSGL-1, termed 6-sulfo LacNAc (slan) 57. Initially, slan+ cells 
were considered to be part of the DC lineage because of major functional similarities they 
share with DCs, i.e. efficient T cell priming 2, 57, 58. However, recent transcriptomic analysis 
revealed that slan+ cells cluster together with non-classical monocytes, suggesting that slan+ 
cells originiate from the monocytic lineage 59. The marker slan is present on roughly 50 % of 
human non-classical monocytes, which is why slan+ cells are now called slan+ monocytes 
(slanMo). Considering the ratios of monocytes and non-classical monocytes, slanMo typically 
constitute around 1.0 – 1.5 % of peripheral blood mononuclear cells (PBMCs) in healthy 
donors. Compared to classical DC populations, which usually make up less than 1 % of 
PBMCs, slanMo represent a high frequency, DC-like population in the human system 60. 
3.2.1.1 Patrolling monocytes in humans and mice 
Human monocytes are conventionally divided into 3 separate groups based on the 
expression of CD14 and CD16, encompassing classical CD14+CD16- monocytes, 
intermediate CD14+CD16+ monocytes, and non-classical CD14-CD16+ monocytes 1. 
Recently, it was described that classical monocytes give rise to intermediate and non-
classical monocytes, reminiscent of a developmental hierarchy 61. In mice, monocytes are 
classified based on the marker Ly6C. Ly6Chigh cells are homologous to human classical 
monocytes, whereas Ly6C- cells are called patrolling monocytes and are suspected to be 
homologous to human non-classical monocytes 59. In fact, a similar developmental hierarchy 
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exists for murine Ly6Chigh cells, which function as the precursors for Ly6C- patrolling 
monocytes 62. As the name already suggests, patrolling monocytes have the ability to crawl 
along and monitor the vasculature for endothelial damage. This phenotype is described for 
both human non-classical monocytes and murine Ly6C- monocytes, which is why also 
human non-classical monocytes are often referred to as patrolling monocytes 63. By using 
genetic knockout mice, Hanna et al demonstrated that Ly6C- monocyte development 
depends on the transcription factor Nur77 (NR4A1), a transcription factor also upregulated in 
their human counterparts 64. Both human and murine patrolling monocytes can be identified 
as CX3CR1highCCR2- cells with high TNF-α production potential 59.  
3.2.1.2 Dendritic cell (DC)-like functions of slanMo 
As previously mentioned, slanMo were initially regarded as circulating blood DCs based on 
their cytokine production and T cell priming capability. T cells cultured with autologous 
slanMo in the presence of recall antigens such as Tetanus toxoid (TT) or keyhole limpet 
hemocyanin (KLH) exhibited increased proliferation. Exposure to tyrosinase-peptide loaded 
slanMo greatly increased antigen-specific T cell responses. In both stimulation techniques, 
slanMo were superior to CD14+ monocytes in promoting T cell function 2. Compared to cDCs 
as the classical APCs, slanMo proved to be slightly inferior in T cell priming 57. 
Another hallmark of DC biology is the release of stimulatory cytokines, in particular IL-12, 
which is a potent T cell and NK cell activating factor. It was demonstrated that slanMo 
account for even stronger IL-12 production than cDCs in vitro 58. However, this is reliant on a 
pre-incubation period of several hours, reminiscent of a maturation phase often required for 
monocyte development. If left undisturbed for 6 hours before stimulation, slanMo can 
become the major producers of IL-12 among PBMCs 58. As part of the innate immune 
system, slanMo carry several PRRs, with TLRs being the strongest drivers of cytokine 
responses 65, 66. In this context, strong induction of IL-12 is reported for various ligands, 
including LPS signaling via TLR4 and R848 signaling via TLR7 and TLR8, reaching 
concentrations not matched by equally stimulated DC populations or CD14+ monocytes 58, 65, 
66. Of note, also CD40-CD40 ligand interactions are capable of triggering IL-12 expression 58. 
Similar to IL-12, slanMo are also potent producers of the pro-inflammatory cytokine TNF-α, 
which is secreted at low levels in steady state and at strongly elevated levels after TLR 
stimulation 2, 67. Autocrine TNF-α is important for expression of other cytokines, such as IL-23 
68. Other reports were not able to reproduce this major role in cytokine production and T cell 
stimulation for slanMo 59, 69. However, these experiments lacked the necessary maturation 
period prior to stimulation, thus rendering the results incomparable to previous findings. 
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In the blood, slanMo are regulated by erythrocytes, which control their activation via CD47 – 
signal-regulatory protein α (SIRPα) interactions. SIRPα signaling on slanMo efficiently 
reduces TNF-α and IL-12 production, thereby regulating the inflammatory potential of those 
cells in the circulation 58.  
3.2.1.3 Tissue distribution of slanMo 
Research on the tissue distribution of non-classical monocytes is still hampered by the lack 
of specific markers, since conventional gating strategies using multiple markers are not 
feasible for histological analysis up to date. In this context, the stable marker slan, which can 
be detected with the specific clones M-DC8, DD1 and DD2 2, 57, opens up the possibility to 
investigate the slanMo subset in situ. 
slanMo, and non-classical monocytes in general, strongly express the CX3C receptor 1 
(CX3CR1), a feature that additionally separates monocytes subsets because classical 
monocytes lack this receptor completely 70. The respective ligand, CX3CL1 (fractalkine), is 
reported to be expressed on the endothelial lumen in a membrane bound form and            
pro-inflammatory cytokines such as TNF-α and IFN-γ can upregulate CX3CL1 surface 
expression 71. CD16+ monocytes (including non-classical and intermediate monocytes) that 
express CX3CR1 strongly adhere to the vasculature. However, active transmigration is 
reported to be hampered in the context of endothelial CX3CL1 expression, preferentially 
allowing CX3CR1- CD14+ monocytes to extravasate to sites of inflammation 71. 
In line with the previously described DC phenotype, slanMo can acquire either a DC-like or a 
macrophage-like phenotype in tissues, being described as either 
CD163lowCD14lowCD64lowCDlow or CD163highCD14highCD64highCD16high, respectively 70. 
Morphologically, slan+ cells acquire a dendritic shape with visible dendrites in tissues 72, 73. 
However, slan+ cells can also exhibit a round, more monocytic appearance, in particular in 
close proximity to vessels. In steady state, slanMo numerously populate tonsils, but are rare 
in other tissues. In an inflammatory setting, slanMo were shown to infiltrate multiple sclerosis 
lesions 74, lupus nephritis 75, atopic dermatitis 76, psoriasis 65, and different tumor entities 70. 
Regarding their presence in the tumor microenvironment (TME), a predominant role in lymph 
node metastasis appears prevalent, as a big study detected slanMo solely in metastatic 
tumor draining lymph nodes of carcinoma patients but not in the primary tumor 73. 
Additionally, slanMo are present in affected lymph nodes of B-cell lymphoma patients and 
mediate anti-tumor responses 72. 
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3.2.1.4 Interactions of slanMo with tumor cells 
slanMo can carry out versatile anti-tumor functions. As described before, slanMo possess 
effective T cell stimulatory potential, which allows them to prime cytotoxic T cells for specific 
tumor antigens. Combination with a modular slan targeting antigen delivery system greatly 
increases antigen specific T cell proliferation 77.  
The general activation status of slanMo in the tumor microenvironment is still largely unclear. 
However, cellular interactions with tumor cells can activate slanMo in vitro in the presence of 
additional IFN-γ and stimulate TNF-α production 60. In addition, slanMo mediate direct tumor 
cell lysis via a TNF-α mediated mechanism. Due to very high expression of the Fc γ 
Receptor III (CD16) on the surface of slanMo, tumor cell lysis is far increased for opsonized 
tumor cell targets, referred to as antibody-dependent cellular cytotoxicity (ADCC) 61. In this 
case, slanMo receive additional activation signals through CD16-mediated ITAM signaling 
leading to increased TNF-α production 61.  This mode of activation is also of relevance in 
other settings, i.e. in lupus nephritis, where immune complexes represent a major hallmark of 
the disease  57. As part of the mononuclear phagocyte lineage, slanMo are also specialized 
at phagocytizing tumor cells and tumor cell debris. This function is documented for different 
tumor types in vitro and in vivo 54, 55.  
Tumors can also exert immune suppression, a phenomenon well described for T cell 
exhaustion in the TME. Similarly, it is reported that circulating slanMo exhibit reduced 
numbers and function in multiple myeloma patients 80. Another factor of immune suppression 
can stem from chemotherapeutic therapy affecting immune cells as a side effect. Here, a 
heterogenous picture arises because slanMo are reported to be functionally impaired in vitro 
by doxorubicin, vinblastine, and bortezomib, whereas mitomycin-c, methothrexate, and 
paclitaxel have no impact on slanMo function 81. 
3.2.2 Natural Killer (NK) cells 
In humans, NK cells comprise around 10-15 % of PBMCs and are classically divided into 2 
subsets based on expression of the neural cell adhesion molecule (NCAM), which is also 
expressed on glia cells and neurons in the brain. In the case of NK cells, NCAM is most often 
referred to as CD56. A smaller subset of around 10-15 % of total NK cells expresses strong 
levels of CD56 and very low levels of CD16, thus being identified as CD56highCD16neg. In 
contrast, the majority of NK cells exhibit intermediate CD56 and high CD16 expression, 
hence being referred to as the CD56dimCD16high subset 82, 83.  
NK cells are part of the lymphocytic lineage despite relying on innate mechanisms, which has 
generated for them the term innate lymphoid cells (ILCs). However, the group of ILCs 
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contains additional subpopulations, notably ILC1, ILC2, ILC3, and lymphoid tissue inducer 
(LTi) cells, all defined by different combinations of surface molecules 84, 85. 
3.2.2.1 Activating and inhibitory receptors on NK cells 
Human NK cells are regulated by a multitude of germline-encoded cell surface receptors 
transmitting either activating or inhibitory signals, thereby allowing to precisely fine-tune their 
activation status. A group of receptors called natural-cytotoxicity receptors (NCR) includes 
Nkp46, Nkp44, and Nkp30, which all represent major activating receptors. Additionally, 
NKG2D and DNAM-1 bind to stress-induced ligands on tumor or virus-infected cells and are 
known to stimulate NK cells and induce cytotoxicity 86. Expression of CD16 enables 
recognition of antibody-coated target cells. In particular, CD16 binding to Fc parts of bound 
IgG greatly increases killing of target cells by ADCC and cytokine secretion. In general, NK 
cell activating receptors use different intracellular adapter molecules to transmit activating 
signals, including ITAM and DNAX-activating proteins (DAP) 10 and DAP12 87. 
Besides activation through cellular contacts, NK cells also strongly respond to cytokines. 
Consequently, NK cells express an array of cytokine receptors, notably IL-1 receptor (IL-1R), 
IL-2R, IL-12R, IL-15R, IL-18R, IL21R, IFN-α receptor (IFNAR) 88. Cytokine signaling in NK 
cells is required for different biological processes. The cytokines IL-2 and IL-15, whose 
respective receptors also share the same β-chain (CD122) and γ-chain (CD132) receptor 
sub-complexes, are important for NK cell maturation and proliferation 89, 90. However, IL-15 
has stronger activation capability when presented in trans on the membrane bound to the   
IL-15R α-chain 91. IL-2 is provided by activated T cells, whereas monocytes and DCs are the 
major source of IL-15. 
The activating IL-12R and IL-18R bind to IL-12 and IL-18, respectively, which are cytokines 
produced by monocytes, macrophages, and DCs. IL-12, in particular, is pivotal in inducing 
cytotoxicity and cytokine production by NK cells. It is composed of two subunits, IL-12p35 
(IL-12A) and IL-12p40 (IL-12B), together forming the bioactive p70 heterodimer. The p40 
subunit is shared with another cytokine, IL-23, which is composed of IL-12p40 and IL-23p19. 
In general, IL-12R signals via phosphorylated STAT4 and thereby triggers cytokine 
production, predominantly IFN-γ, and cytotoxicity by upregulation of activating receptors 92. 
Recently, a special role of synergistic cytokine combinations became apparent. In particular 
combined IL-12, IL-15, and IL-18 are uniquely potent in stimulating both human and murine 
NK cell anti-tumor immune responses 93, 94, 95. Of note, IL-12 can potentially also act 
regulatory, as NK cell apoptosis after combined IL-12 and IL-2 exposure is reported, 
suggesting a mechanism to prevent excess or chronic IL-12 mediated inflammation 96. 
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NK cell cytotoxic and pro-inflammatory function can pose severe threats to tissues. 
Therefore, to balance NK cell activity under extensive presence of activating ligands, NK 
cells readily express inhibitory receptors responsible for preventing tissue damage 86. Most 
prominently, killer immunoglobulin-like receptors (KIRs) recognize MHC I molecules and 
convey inhibitory signals to NK cells via immunoreceptor tyrosine-based inhibitory motifs 
(ITIM) signaling 97. Owing to constant expression of MHC I on all nucleated cells, the loss or 
downregulation of MHC I on tumor or virus-infected cells is recognized by NK cells through 
omitting inhibitory signals. Other major inhibitory receptors include CD94/NKG2A, Killer cell 
lectin-like receptor subfamily G member 1 (KLRG1), and T cell immunoreceptor with Ig and 
ITIM domains (TIGIT), all of which signal via ITIMs to regulate the activation status of NK 
cells  86. 
3.2.2.2 Cytokine-production by NK cells 
The signature cytokine produced by NK cells is generally considered to be the type II 
Interferon IFN-γ 98. Consequently, NK cells represent an immediate innate source of IFN-γ, 
before Th1 immunity takes over. Other cytokines and chemokines secreted by NK cells after 
appropriate stimulation include TNF-α, granulocyte macrophage-colony stimulating factor 
(GM-CSF), CCL3/4/5, IL-8, and the C-type chemokines XCL1 and XCL2. While the secreted 
chemokines can mediate recruitment of other immune cell populations, i.e. DCs via the 
CCR5 ligands CCL3/4/5, IFN-γ and TNF-α are largely involved in initiating and maintaining 
immune responses 99. TNF-α is considered an acute phase protein due to its early 
expression in inflammation and its effects on the endothelium, where it mediates vasodilation 
and activation of endothelial cells. IFN-γ predominantly activates monocytes, macrophages, 
and DCs, thereby often supporting maturation and fueling cytokine production.  
3.2.2.3 Migratory aspects of NK cells and presence in tissues 
Since NK cells constitute around 10 % of PBMCs, they form a major circulating population 
capable of infiltrating distant tissues in large numbers, especially in inflammation. Under 
homeostatic conditions, NK cells readily populate the liver, lung, lymphoid tissues, and 
uterus 100. Owing to fundamental differences in chemokine receptor expression between the 
two NK cell subsets, homing of CD56bright and CD56dim cells deviates strongly in both steady-
state and inflammation 101, 102. Whereas CD56bright NK cells can be detected in SLOs owed to 
expression of CXCR3, CCR7, and L-selectin, CD56dim NK cells are rather characterized by a 
receptor repertoire allowing them to infiltrate inflamed tissues 103, 104. Specifically, CD56dim NK 
cells express CXCR1, CXCR2, CXCR4, CCR2, CX3CR1, and chemerin receptor 23 
(Chem23), of which Chem23 binds to the unconventional chemokine chemerin 102, 103, 105, 106, 
107. Interestingly, chemokine receptor variations relatively accurately align with differential 
22 
 
  
tissue distribution. In this way, under steady state, CD56bright NK cells form the major NK cell 
subset in mucosa-associated lymphoid tissue (MALT), liver, kidney, uterus, adrenal gland, 
and visceral adipose tissue 100. On the other hand, CD56dim NK cells preferentially populate 
the bone marrow, spleen, lung, and breast.  
Inflamed vasculature is prepared for increased influx of immune cells. Typical chemotactic 
mediators of inflammation are IL-8, CCL2-5, and CXCL10, broadly matching with CD56dim NK 
cell receptor expression 102. In line with this, in many inflammatory mouse models, such as 
herpes simplex virus or influenza, NK cells were critical in mediating anti-viral immunity 108. 
Besides the well-documented role of NK cells in virus infection, detailed descriptions of NK 
cell infiltration in chronic inflammatory diseases, autoimmune diseases and cancer, are less 
well studied. Infiltration into tumor tissue is dictated by different factors. On the one hand, 
tumor cells often dampen immune responses through an anti-inflammatory environment, 
thereby also hampering immune cell chemokine crosstalk. On the other hand, tumor cells are 
capable of directly modifying the tumor microenvironment by selective secretion of 
chemokines, which allows them to modulate immune cell infiltration. Finally, NK recruitment 
into tumor tissue is often rendered futile due to NK cells also suffering under tumor mediated 
immunesuppression. However, NK cells are reported to be present in cervical cancer 109, 
breast cancer 110, melanoma metastasis 111, 112, and other tumor entities 84. An increasing 
body of evidence suggests that NK cells exert a pivotal role in protection from metastasis. 
Various reports state absence of NK cells in the primary tissue, but active infiltration into, and 
reduction of, metastasis 113. However, the reason why NK cells are most often ineffective in 
primary tumor tissue and appear to only exert anti-metastatic activity remains largely 
unknown.  
Apart from NK cells, other ILC populations are less well characterized in human tissues and 
pathologies. This is majorly owed to their recent discovery and the requirement to include 
multiple markers for reliable detection of individual ILC population 84. However, the 
phenotype and composition of ILCs in human tissues appears to be very heterogenous, as 
an initial study suggests 114. 
3.2.2.4 Anti-tumor functions of NK cells 
NK cells are important for two major anti-tumor functions, notably direct cytotoxicity and IFN-
γ production. The mechanisms by which NK cell mediated tumor-directed cytotoxicity can 
occur are well studied and either involve secretion of lytic granules filled with perforin and 
granzymes or surface expression of death receptors 115. Perforin and granzymes are the 
classical NK cell and cytotoxic CD8 T cell effector molecules, which induce apoptotic cell 
death in target cells 116. Mechanistically, NK cells form cytotoxic synapses through which the 
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secretion of lytic granules is spatially controlled. Perforin released after degranulation 
permeabilizes the target membrane by forming pores through which granzymes can enter 
the cytoplasm. Inside the target cell, granzyme B (GzmB) activates the key apoptosis-
inducing caspase-3, thereby initiating GzmB-mediated apoptosis 116. Importantly, cathepsin B 
and LAMP-1 (CD107a) protect the effector cells against perforin-associated damage 117, 118. 
Cytotoxicity via death receptors relies on direct binding of target cells. This can occur with 
different receptor-ligand interactions, most prominently Fas-FasL, TRAIL-TRAILR, and            
TNF-TNFR. In general, triggering of death receptors culminates in the formation of the death-
inducing signaling complex (DISC), which then initiates apoptosis 116. Both modes of inducing 
cell death have been reported to mediate tumor destruction in mouse models 119, 120. 
Besides direct cytotoxicity, NK cells can influence tumor cells by secretion of IFN-γ. IFN-γ 
can increase MHC I expression on target cells, thereby facilitating adaptive immune 
responses. Besides, IFN-γ increases the sensitivity of target cells towards apoptosis by 
upregulation of death receptors 99. Interestingly, IFN-γ was also found to restrict proliferation 
in different cell types, and the combination of TNF-α and IFN-γ, both of which are also 
produced by NK cells, is reported to induce a senescent state in tumor cells 121, 122, 123. In line 
with this, an anti-proliferative role of NK cells stimulated with PDGF-DD is reported against 
tumor cells 124. 
3.2.3 The slanMo/NK cell crosstalk in the tumor microenvironment 
The crosstalk between innate immune cells often solely relies on soluble interactions, since 
no direct cell-cell contact like in antigen-receptor mediated T cell priming is required. 
Therefore, innate immunity possesses a versatile cytokine and chemokine system ideally 
suited to initiate immune responses. 
slanMo are major producers of IL-12 among PBMCs 58. Even though no experimental 
evidence for their cytokine-production in tissues is available, it can be assumed that they can 
achieve a potent pro-inflammatory state after exiting the periphery. NK cells respond with 
strong IFN-γ production towards IL-12 92. In turn, IFN-γ potently stimulates slanMo 
responses. In line with this, slanMo/NK cell co-cultures exhibit a synergistic positive feedback 
fueled by slanMo-derived IL-12 and NK cell-derived IFN-γ (Fig. 3.3). It is reported that this 
bidirectional crosstalk is started by presentation of membrane-bound TNF-α (mTNF-α) on the 
surface of slanMo after appropriate stimulation with TLR ligands such as LPS 125. 
Concomitantly, NK cells upregulate TNF receptor (TNFR2) during the co-culture, leading to 
NFκB signaling. This results in expression of common NFκB targets, of which GM-CSF 
supports IL-12 production by slanMo 125. At this point, the positive feedback loop takes over, 
reaching very high levels of IL-12 and IFN-γ.  
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In addition, NK cells upregulate the activation marker NKp46, NKp44, and NKp30 after 
contact with TLR-activated slanMo 126. In line with this, tumor-directed cytotoxicity is also 
significantly increased after co-culture. In a reciprocal fashion, NK cells support slanMo 
maturation by increasing slanMo surface expression of CD83, CD86, ICAM-1, and HLA-DR, 
and reducing inhibitory IL-10 production. While NK cell activation is IL-12 mediated and 
therefore largely cell-contact independent, the reciprocal slanMo stimulation is partially      
cell-cell contact dependent 126.  
 
Figure 3.3 – Graphical illustration of the slanMo / NK cell crosstalk. The synergistic bidirectional 
stimulation is mediated by IL-12 and TNF-α produced by TLR-activated slanMo and NK cell-derived 
IFN-γ that activates slanMo. This interaction elevates the expression of HLA-DR and the maturation 
markers CD83 and CD86 on slanMo. Immunosuppressive IL-10 production by slanMo is reduced after 
contact with NK cells. NK cells upregulate the surface markers NKp46, NKp44, NKp30, and exhibit 
higher cytotoxicity. 
3.2.3.1 The patrolling monocyte / NK cell crosstalk in mice 
Mouse models often give valuable mechanistic insights that can be translated to the human 
system. Based on previous studies, murine patrolling monocytes appear to exhibit a high 
functional homology to human non-classical monocytes, and therefore also to the 
subpopulation of slanMo 59. Murine patrolling monocytes are involved in detection and 
elimination of metastasis in tumor models of lung carcinoma and melanoma 53. Interestingly, 
this mechanism further relied on recruitment of NK cells to the site of metastasis. In line with 
this, another study reported a role for the murine patrolling monocyte and NK cell crosstalk in 
reducing metastatic load 127. In detail, primary tumors were required to stimulate IL-15 
production by murine patrolling monocytes, which then activated NK cell IFN-γ production. 
Furthermore, it is reported that murine patrolling monocytes can become activated by cancer 
exosomes and thereby limit metastasis. However, this effect was reliant on pigment 
epithelium-derived factor (PEDF) on the surface exosomes, which was interestingly only 
present on exosomes from non-metastatic cancers 128. 
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Together, this strongly suggests a major role of patrolling monocytes in mediating metastasis 
rejection, in particular through interaction with NK cells. 
3.3 Tumor biology 
3.3.1 Malignant transformation 
The process of malignant transformation turns healthy cells into cancers with uncontrolled 
proliferation, often leading to mortality in patients. Several safeguard mechanisms exist, 
which usually prevent that single mutations result in malignancy. Thus, for single cells to 
achieve a malignant state requires the accumulation of multiple mutations, together nullifying 
all relevant safeguard mechanisms. Mutations arise through DNA damage. Despite several 
DNA repair mechanisms existing in healthy cells, DNA damage can ultimately result in 
permanent genetic modifications. There are ample causes of mutagenesis, most common 
factors are however ultraviolet- (UV-) or γ-irradiation from the sun, and ingested or inhaled 
genotoxic substances. Oncogenesis-related genes are classified in two groups, oncogenes 
and tumor-suppressor genes: 
Mutations in oncogenes, leading to upregulation or continuous activation, are the major 
drivers of malignant transformation. Often, oncogenes provide constant proliferative signals, 
thereby enabling unrestricted proliferation. A prominent example are mutations in the protein 
NRAS in melanoma. Despite KRAS being most commonly mutated over all cancer entities, 
highest RAS mutation frequencies in melanoma occur in NRAS 129, 130. Mutations that render 
NRAS constitutively active initiate downstream signaling predominantly via RAS-RAF-MAPK 
and PI3K pathways. Continuous signaling then provides pro-survival signals, affects cell-
cycle deregulation, and thereby induces proliferation 129, 130. In this regard, NRAS mutations 
alone already cover many of the hallmarks of cancer described in 2011 by Hanahan and 
Weinberg, which state that tumor cells require the ability to sustain proliferative signaling, 
evade growth suppression, resist cell death, induce angiogenesis, enable replicative 
immortality, activate invasion and metastasis, deregulate cellular energetics, and avoid 
immune destruction  131. Due to this, mutations in targets such as NRAS are often called 
driver mutations.  
Similarly, tumors frequently exhibit loss of or inactivating mutations on tumor suppressors. 
Tumor suppressors represent safeguard mechanisms that prevent unrestricted growth in 
healthy cells. The transcription factor p53 is also referred to as “guardian of the genome”, a 
name that stems from its integral role in the DNA damage response 132. In the event of DNA 
damage, p53 becomes activated and arrests cell growth through induction of target genes 
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such as the cyclin-dependent kinase (CDK) inhibitor (CDKI) p21 (CDKN1A) 121, 133, 134. The 
arrest in cell cycling allows the DNA repair machinery to correct mutagenic events. However, 
if DNA repair is unsuccessful, p53 can dictate the cell’s fate in one of two ways: Either 
apoptosis pathways become activated and eliminate potentially mutagenic cells, or the cells 
enter a state of permanent growth arrest called senescence 135. Senescent cells are arrested 
in the G0/G1 state of the cell cycle and are believed to have lost the ability to re-enter the 
active cell cycle. 
3.3.2 Melanoma  
Melanoma is a tumor originating from melanocytes in the skin. Other common types of skin 
cancer include squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Yet both 
are generally considered to be less aggressive than melanoma.  
Activation of oncogenes and suppression of tumor suppressors together form the path for 
oncogenesis. In this regard, each tumor entity has different signatures of commonly mutated 
genes, and also individual tumors often exhibit markedly different mutational patterns than 
tumors of the same origin. Interestingly, also the general mutational load varies strongly 
between tumor entities. Melanoma typically exhibits one of the highest mutational burden of 
all types of tumors, which appears reasonable considering the constant UV irradiation 
exposure of the skin as a major mutagenic factor. As mentioned before, melanomas 
commonly incorporate specific driver mutations, most prominently BRAF, NRAS, p16INK4A, 
and p53. In fact, around 50% of melanoma patients harbor a BRAF V600E mutation, 
highlighting the importance of constitutively active signaling kinases in melanoma 
development 129. 
From a clinical perspective, melanoma is classified regardless of mutational status. Due to 
the easy visual accessibility of melanocytic tumors, the basic determination of malignancy is 
made upon visual examination. Discriminating factors include the size, shape, contour and 
color. Malignant cutaneous tumors are then further classified according to the stage of 
progression. For stages prior to metastasizing, this relies the size of the tumor, summarizing 
non-ulcerated tumors below 1 mm in radius as stage I melanoma and tumors above 1 mm as 
stage II. Stage III encompasses melanomas with involvement of regional lymph nodes. With 
the detection of distant metastasis, melanomas fall under the stage IV category 136. 
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3.3.3 Melanoma Therapy 
Melanomas very frequently incorporate driver mutations in the serine/threonine-protein 
kinase BRAF. This high prevalence of a single driver mutation with a pivotal role in initiating 
and maintaining a malignant state also opens up avenues for therapeutic intervention. First 
targeted therapies against melanoma were approved in 2011, are still developed further and 
are applied in the clinics today. Vemurafenib is a selective BRAF-mutant inhibitor that 
achieves initial tumor regression in around 90 % of patients. However, tumor regression is 
generally transient, since melanomas rapidly acquire additional mutations in other pathways 
which substitute for the key role of BRAF 137.  
Another more recent therapeutic approach arises from tumor immunology. Immune 
checkpoint inhibitors neutralize surface molecules that would otherwise severely dampen 
local immune reactions. Two types of therapeutics, either binding to PD-1 or CTLA-4, are 
currently used in the clinic with unprecedented response rates in melanoma. Mechanistically, 
PD-1 and CTLA-4 are expressed by activated T cells and cause T cell exhaustion through 
binding to PD-L1 on tumor cells and CD80/86 on antigen presenting cells. This inhibitory axis 
is relieved through blocking with neutralizing antibodies, which boosts T cell responses. 
However, still only a fraction of patients respond to checkpoint inhibitor therapy and side 
effects are immense, typically including chronic inflammatory diseases triggered by 
overshooting immune responses. Nevertheless, checkpoint inhibitor immunotherapy 
represents the biggest breakthrough in cancer therapy over the last years 137.  
Another rare line of therapy involves topical application immune stimulatory agents such as 
the TLR 7/8 ligand Imiquimod for cutaneous melanoma 138. This application is under 
investigation for its use as supportive treatment after initial melanoma excision and to induce 
melanoma regression where operation is not feasible 139, 140. 
3.4 Senescence in tumors 
Senescence describes a permanent stop in cell cycle progression, where the cells remain in 
a G0/G1 arrest. This has important implications with regard to oncogenesis, since 
senescence is a common response to mutations and oncogene activity, a process called 
oncogene-induced senescence (OIS). OIS is only one trigger that can cause cellular 
senescence. Additionally, senescence can be a result of the DNA damage response, it can 
occur as replicative senescence induced by telomere shortening, or it can be triggered 
through tumor suppressor activation or oxidative stress 141. Senescent cells are characterized 
by strongly reduced proliferation reminiscent of a complete growth arrest, changes in 
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heterochromatin organization, and through an enlarged and flattened morphology. Another 
widely used marker for senescent cells is senescence-associated β-Galactosidase           
(SA-β Gal), a lysosomal enzyme consistently upregulated in senescent cells 142. Recently, 
the secretome of senescent cells has become a major field of study. The so called 
senescence-associated secretory phenotype (SASP) is characterized by the secretion of a 
range of particular soluble factors. The SASP includes inflammatory cytokines and 
chemokines such as IL-6, IL-8, IL-1α, IL-1β, and CXCL-1, extracellular matrix (ECM) 
modifying enzymes such as the matrix metalloproteinases (MMPs) MMP-1 and MMP-2 143, 
angiogenesis-related factors such as VEGF, and immune suppression mediators such as 
TGF-β 144.  
3.4.1 Regulation of the cell cycle 
During the mammalian cell cycle, different groups of proteins cooperate to initiate, maintain, 
and regulate cell division after receiving mitotic signals. The cell cycle is divided in four 
phases (Fig. 3.4): The G1 phase, where cells grow in volume in order to prepare for the 
second phase, the S phase. During the S phase, the diploid (2n) genetic material is 
duplicated in a way that each daughter cell receives a complete diploid set of chromosomes. 
In the subsequent G2 phase, the cells continue to grow and accumulate organelles before 
entering mitosis, which is called the M phase, and which ultimately yields the generation of 
two identical daughter cells. Importantly, the cell cycle has safeguard mechanisms in the 
form of checkpoints that restrict progression to the next phase in order to prevent 
transmission of mutated genetic material to the progeny. During the G1/S phase transition, 
cells examine the DNA for damage and proceed with DNA replication only in the absence of 
DNA-damage response signals. Similarly, cells control successful DNA synthesis during the 
S phase and prolong the G2 phase in case of DNA damage prior to entering the M phase.  
Progression to the next phase is mediated by cyclically expressed cell cycle proteins called 
cyclins and cyclin-dependent kinases (CDKs) (Fig. 3.4). Importantly, specific cyclin – CDK 
pairs are active during defined cell cycle phases and are required for advancing to the next 
phase. D Cyclins coupled to CDK4 and CDK6 are active during the G1 phase. CDK2-cyclin E 
and CDK2-cyclin A complexes are required for G1/S transition and the S phase, respectively. 
Finally, CDK1 can interact with cyclin A and cyclin B to initiate and undergo mitosis. Despite 
control through constant degradation of cyclins, CDKs are thoroughly regulated by CDK 
inhibitors (CDKi). Two groups of CDKi’s control CDK-enabled cell cycle progression. p16INK4a 
(CDKN1A), short p16, belongs to the INK4 protein family and inhibits CDK4/6 – cyclin D 
complexes 145. This arrests cells in the G1 phase by preventing progression to the S phase. 
In fact, p16 expression can terminally arrest proliferation and keep the cells in a senescent 
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G0/G1 arrest. Similarly, p21, as a member of the CIP/KIP family, encompassing p21, p27, and 
p57146, predominantly targets CDK1- and CDK2 - cyclin complexes 146. In this way, p21 can 
prolong both the G1 and G2 phase and thereby mediate senescence through a G0/G1 and 
G2/M arrest, respectively. 
 
Figure 3.4 – Modulation of the cell cycle by CDK inhibitors. General scheme of the cell cycle 
including G1 phase, where cells prepare for DNA replication during the S phase. This is a followed by 
second preparation phase, the G2 phase, after which the cells undergo mitosis in the M phase. As 
depicted, different cyclin – CDK complexes control each cell cycle phase. p21cip1 and p16INK4a 
represent CDK inhibitors (CDKI) that regulate CDKs during cell cycle progression. CDK (Cyclin-
dependent kinase).  
3.4.2 Senescence pathways 
p21 and p16 are downstream effectors of the two major senescence pathways: The p53-p21 
and the p16-Retinoblastom (Rb) pathway. As mentioned before, p53 is activated during the 
DNA-damage response and mediates the decision between apoptosis and senescence. 
Apoptosis is mediated through induction of pro-apoptotic targets such as the BH3-only 
members BIM, PUMA, and NOXA, which inhibit anti-apoptotic Bcl-2, thereby ultimately 
triggering apoptotic cell death 147. 
Alternatively, p16 can be triggered by cellular stress, i.e. DNA damage, oncogenic stress, 
and as a homeostatic factor during aging. By targeting Cyclin D – CDK complexes, p16 
inhibits phosphorylation of the tumor suppressor Rb. Rb phosphorylation is required to 
release the transcription factor E2F, which is required for progression to the S phase. In this 
way, consistent p16 expression induces a permanent G0/G1 arrest 148. 
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3.4.3 Deregulation of the cell cycle in tumor cells 
Due to several levels of cell cycle regulation, tumor cells are often forced to acquire multiple 
mutations in cell cycle genes, of which many are considered driver mutations 149. Most 
prominently, melanoma, but also other tumor entities, often incorporate loss of function 
mutations in p53, p16, and less frequently p21, thereby crippling the two major DNA-damage 
response-associated pathways 150. On the other hand, tumors can also directly modify cell 
cycle progression mediators by overexpression of D cyclins and CDK4/6. This shows that 
tumor cells frequently target the G1/S checkpoint, highlighting the importance of the G0/G1 
arrest in limiting propagation of mutations. As a result, several CDK inhibitors are currently 
tested in clinical trials 151. Despite limited success to date, CDK inhibitors could profit from 
observations gained in mouse studies that suggest that development and growth of most 
tissues are only dependent on CDK1 for functional cell division and can compensate for loss 
of CDK2/4/6 152. This opens up avenues for selectively targeting of specific CDKs. However, 
it is unclear whether tumors actually require certain CDKs to be deregulated, or if 
compensatory mechanisms would be able to substitute 150. 
3.4.4 Cytokine-induced senescence 
Senescence is commonly triggered to prevent propagation of defective genetic material. 
Recently, Röcken et al. demonstrated that the combination of the pro-inflammatory cytokines 
TNF-α and IFN-γ, secreted by Th1 cells, induces senescence in a β-islet cancer mouse 
model 123. In this model, senescence is strictly reliant on both TNF receptor (Tnfr) and IFN-γ 
induced STAT1 signaling. Besides, TNF-α and IFN-γ were previously also independently 
associated with cell cycle regulation and senescence. IFN-γ can induce p27 upregulation in 
rat embryonic fibroblasts and senescence in melanocytes through p21 122, 153. Similarly,     
TNF-α upregulates p21 and p27 in glioblastoma cell lines and mediates senescence in 
human umbilical vein endothelial cells (HUVECs) through maintaining a chronic DNA-
damage response. In addition, common SASP factors, such as TGF-β, IL-6, and IL-8, are 
also associated with inducing senescence 144. This generates an interesting concept, in 
which senescence is maintained through senescence-induced autocrine factors. 
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3.5 Aim of the Study 
Despite recent breakthroughs associated with checkpoint inhibitor therapy of melanoma, 
treatment only achieves long-term survival in a fraction of patients, which is largely owed to 
frequent evasion of T cell responses through mutations in the antigen presentation 
machinery. Thus, novel avenues for targeting T cell resistant patient populations are urgently 
needed. Innate immunity is not dependent on antigen-specific receptors and clonal 
proliferation, but instead relies on a broad variety of germline encoded receptors adapted to 
recognize disease-associated patterns. slanMo and NK cells are innate immune cells that 
engage in a synergistic crosstalk increasing both tumor-directed cytotoxicity and cytokine 
production. However, the influence and anti-tumor potential of this crosstalk in malignant 
melanoma is poorly explored. 
Here, we aim to elucidate the following aspects of the intratumoral crosstalk between slanMo 
and NK cells: 
1) The detection and quantification of slanMo and NK cells in melanoma, including the 
resolution of kinetic aspects by analyzing all stages of melanoma development. 
2) The characterization of the chemokine milieu generated by slanMo combined with 
migration analysis of NK cells. In detail, we pursued the hypothesis that              
R848-stimulated slanMo recuit NK cells to the TME. 
3) Evaluation of the influence of the R848-stimulated slanMo/NK cell crosstalk on 
melanoma cells. In particular, we wanted to evaluate whether the cytokine milieu 
generated by slanMo and NK cells elicits a senescence phenotype in melanoma cells. 
4) Characterizing the secretion of SASP factors in senescent melanoma cells. 
These investigations will combine functional in vitro data with validation of our cell types in 
patient samples. Together, this provides relevant insight into the modes of action of 
therapeutics aiming at activating innate immune cells, such as the TLR 7/8 ligand imiquimod 
that is used for topical melanoma therapy. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Cell lines 
Cell line Origin Medium 
SK-Mel-25 Human Melanoma cell line RPMI  
SK-Mel-28 Human Melanoma cell line RPMI 
SK-Mel-30 Human Melanoma cell line RPMI 
Ma-Mel-86b Human Melanoma cell line RPMI 
 
All culture medium was supplemented with 10 % FCS, 2 mM L-glutamine, and 1 % 
Penicillin/Streptomycin, unless otherwise stated in 4.2. 
4.1.2 Cell culture consumables 
Product Company  Catalogue 
Conical tubes (15 ml, 50 ml) Cellstar, Frickenhausen, Germany 227261 
Serological pipets (5 ml) Greiner, Frickenhausen, Germany 4487 
Serological pipets (10 ml) Greiner, Frickenhausen, Germany 4488 
Serological pipets (25 ml) Greiner, Frickenhausen, Germany 4489 
Pipette tips (20 µl) Gilson, Limburg, Germany F161450 
Pipette tips (200 µl) Gilson, Limburg, Germany F161930 
Pipette tips (1000 µl) Gilson, Limburg, Germany F161670 
6-well Tissue culture plate Corning, Kaiserslautern, Germany 353046 
12-well Tissue culture plate Corning, Kaiserslautern, Germany 353043 
24-well Tissue culture plate Corning, Kaiserslautern, Germany 353047 
48-well Tissue culture plate Corning, Kaiserslautern, Germany 353078 
96-well microplate, flat-bottom Corning, Kaiserslautern, Germany 353072 
96-well microplate, round-bottom Corning, Kaiserslautern, Germany 353077 
Culture flask (25, 75, 175 cm2) Thermo Fisher, Waltham, MA, USA 156367, 
156499, 
159910 
96 well migration plates, ChemTx Neuroprobe, Gaithersburg, MD, USA 101-5 
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Transwell Permeable Suppport, 5 
µm, 24 well 
Costar, Corning, Kaiserslautern, 
Germany 
3421 
Diagnostic slides 8 well Gerhard Menzel GmbH, Braunschweig, 
Germany 
X1XER301
B 
4.1.3 Cell culture reagents 
Product Company  Catalogue 
Fetal bovine serum Sigma, Steinheim, Germany F7524 
EDTA Applichem, Darmstadt, Germany A2937 
Phosphate buffered saline (PBS) Thermo Fisher, Waltham, MA, USA 14190144 
Biocoll seperating solution Biochrom, Berlin, Germany L6115 
Human Serum Sigma, Steinheim, Germany H4522 
Penicillin/Streptomycin GE Healthcare, Munich, Germany P11-010 
L-Glutamine GE Healthcare, Munich, Germany M11-004 
MEM non-essential amino acids Sigma, Steinheim, Germany M7145 
Sodium pyruvate Sigma, Steinheim, Germany S8636 
RPMI 1640 Biochrom, Berlin, Germany F1215 
Human albumin Octapharma, Langenfeld, Germany 00200331 
Trypan Blue Thermo Fisher, Waltham, MA, USA 15250-061 
Trypsin EDTA (10x) GE Healthcare, Munich, Germany L11-003 
Cryomedium (Cryo-SFM) Promocell, Heidelberg, Germany C-29912 
Annexin V reagent Sartorius, Goettingen, Germany 4641 
 
Human and fetal bovine serum was inactivated at 56 °C for 30 minutes prior to application in 
cell culture experiments. 
Cell culture medium for primary human cells: 
Complete RPMI RPMI 1640, 10% human serum, 2 mM L-glutamine, 1 % 
Penicillin/Streptomycin, 1x MEM amino acids, 1 mM 
sodium pyruvate 
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4.1.4 Magnetic activated cell sorting (MACS) 
Product Company  Catalogue 
autoMACS columns Miltenyi, Bergisch Gladbach, Germany 130-021-
101 
NK cell isolation kit Miltenyi, Bergisch Gladbach, Germany 130-092-
657 
Anti-mouse IgM Microbeads Miltenyi, Bergisch Gladbach, Germany 130-047-
301 
CD4+ T cell isolation kit Miltenyi, Bergisch Gladbach, Germany  130-096-
533 
CD14 Microbeads, Human Miltenyi, Bergisch Gladbach, Germany 130-050-
201 
4.1.5 Kits 
Cytokine measurement kits 
Product Company  Catalogue 
LEGENDplex™ Human Anti-Virus 
Response Panel  
Biolegend, San Diego, CA, USA 740390 
LEGENDplex™ Human Cytokine 
Panel 2 
Biolegend, San Diego, CA, USA 740102 
LEGENDplex™ Human 
Proinflammatory Chemokine Panel 
Biolegend, San Diego, CA, USA 740003 
Human TNF ELISA Set BD Biosciences, Heidelberg, Germany 555212 
Human IFN-γ ELISA Set BD Biosciences, Heidelberg, Germany 555142 
 
   Histology kits and reagents 
Product Company  Catalogue 
Dako REAL Detection System Dako, Jena, Germany K5005 
Vectastain® ABC:HRP Mouse IgM Linaris, Mannheim, Germany PK-4010 
Goat anti-Rabbit IgG (H+L):Biotin Linaris, Mannheim, Germany BA-1000 
Histogreen  Linaris, Mannheim, Germany E109 
Avidin/Biotin blocking kit Linaris, Mannheim, Germany SP-2001 
Roti-Histol Carl Roth, Karlsruhe, Germany 6640.5 
Hematoxylin Gill 3 Thermo Scientific, Waltham, MA, USA 6765009 
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Aquaous mounting medium Aquatex, Merck, Darmstadt, Germany 108562 
Xylene based mounting medium Consul Mount, Thermo Scientific 9990440 
Immunofluorescence Mounting 
Medium 
Dako, Jena, Germany S3023 
 
    Western Blot kits and reagents 
Product Company  Catalogue 
BCA Protein Assay Thermo Fisher, Waltham, MA, USA 23225 
ProSieve Color Protein marker Lonza, Basel, Switzerland 850537 
ECL Substrate GE Healthcare, Munich, Germany RPN2235 
 
  Other kits and reagents  
Product Company  Catalogue 
CellTiter-Glo Luminescent Cell 
Viability Assay 
Promega, Mannheim, Germany G7571 
β-Galactosidase staining kit US Biological, Salem, MA, USA G1041-76 
TMB solution ELISA BD Biosciences, Heidelberg, Germany 555214 
Scintillation solution Perkin Elmer, Waltham, MA, USA 1205-440 
4.1.6 Antibodies  
Antibodies for flow cytometry (FACS) 
Primary antibody Clone Company Species Final conc. 
CD56 PE-Cy7 HCD56 Biolegend, San Diego, 
CA, USA 
Mouse IgG1κ 2 µg/ml 
CD56 FITC HCD56 Biolegend, San Diego, 
CA, USA 
Mouse IgG1κ 4 µg/ml 
CD3 APC UCHT1 BD, Heidelberg, 
Germany 
Mouse IgG1κ 1:10 
CD16 PE 3G8 BD, Heidelberg, 
Germany 
Mouse IgG1κ 1:10 
CXCR1 FITC 8F1 Biolegend, San Diego, 
CA, USA 
Mouse IgG2b 4 µg/ml 
CXCR2 PE 5E8 Biolegend, San Diego, 
CA, USA 
Mouse IgG1κ 1.4 µg/ml 
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Isotype control Clone Company Species Final conc. 
mIgG2b FITC MPC-11 Biolegend, San Diego, 
CA, USA 
Mouse IgG2b As CXCR1 
FITC 
mIgG1 PE MOPC-21 BD, Heidelberg, 
Germany 
Mouse IgG1κ As CXCR2 
PE 
 
Sec. control Cat. Company Species Final conc. 
Anti mIgM (anti-slan) 731822 Beckman Coulter, 
Fullerton, CA, USA 
Goat F(ab)2 2.5 µg/ml 
 
  Antibodies for Histology and Western Blot 
Primary antibody Clone Company Species Final conc. 
CD56 123c3 Invitrogen, Carlsbad, 
CA, USA 
Mouse IgG1κ IF: 
13.3 µg/ml 
slan DD2 Hybridoma 
supernatant 
Mouse IgM IHC: 
50 µg/ml 
CD3 SP7 Abcam, Cambridge, 
UK 
Rabbit IgG IHC:  
1:200 
p21 EPR362 Abcam, Cambridge, 
UK 
Rabbit IgG IF/IHC: 5 µg/ml 
WB: 0.5 µg/ml 
Ki67 MIB-1 Dako, Jena, Germany Mouse IgG1κ IF/IHC: 
0.6 µg/ml 
β-actin HRP C4 SantaCruz, 
Heidelberg, Germany 
Mouse IgG1 WB: 
0.2 µg/ml 
 
Isotype control Clone Company Species Final conc. 
mIgM MM-30 Biolegend, San Diego, 
CA, USA 
Mouse IgM As primary 
mIgG1κ MOPC-21 BD, Heidelberg, 
Germany 
Mouse IgG1κ As primary 
rbIgG EPR25A Abcam, Cambridge, 
UK 
Rabbit IgG As primary 
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Sec. antibody Cat. Company Species Final conc. 
Goat anti-rabbit A488 111-545-
003 
Dianova, Hamburg, 
Germany 
goat IF: 2.5 µg/ml 
Goat anti-mouse 
A647 
115-605-
062 
Dianova, Hamburg, 
Germany 
goat IF: 2.5 µg/ml 
Goat anti-rabbit HRP 111-035-
144 
Dianova, Hamburg, 
Germany 
goat WB: 1 µg/ml 
 
   Antibodies for neutralization experiments 
Antibody Clone Company Species Final conc. 
Adalimumab D2E7 Humira, Abbvie, 
Chicago, IL, USA 
Human IgG1 10 µg/ml 
Human IFN-γ B133.5 Hoelzel Diagnostika, 
Cologne, Germany 
Mouse IgG1 10 µg/ml 
Human IL-8 6217 R&D, Abingdon, UK Mouse IgG1 10-20 µg/ml 
Human CCR5 45531 R&D, Abingdon, UK Mouse IgG2b 20 µg/ml 
 
Isotype control Clone Company Species Final conc. 
Human IgG1 isotype Cat: 
BE0297 
Hoelzel Diagnostika, 
Cologne, Germany 
Human IgG1 As primary 
Mouse IgG1 isotype MOPC-21 Hoelzel Diagnostika, 
Cologne, Germany 
Mouse IgG1 As primary 
Mouse IgG2b isotype Mg2b-57 Biolegend, San Diego, 
CA, USA 
Mouse IgG2b As primary 
4.1.7 Chemical reagents and biological compounds 
Product Company  
DAPI (4′,6-Diamidin-2-
phenylindol) 
Sigma, Steinheim, Germany 
Paraformaldehyde (PFA) Sigma, Steinheim, Germany 
Recombinant TNF-α Promocell, Heidelberg, Germany 
Recombinant IFN-γ Immunotools, Friesoythe, Germany 
R848 Life Technologies, Carlsbad, CA, USA 
Lipopolysaccharid (LPS) Sigma, Steinheim, Germany 
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CCL3 Immunotools, Friesoythe, Germany 
CCL4 Immunotools, Friesoythe, Germany 
CXCL-8 (IL-8) Immunotools, Friesoythe, Germany 
CXCL12 (SDF-1) Immunotools, Friesoythe, Germany 
BSA (Bovine Serum Albumin) Sigma, Steinheim, Germany  
Tween 20 Carl Roth, Karlsruhe, Germany 
4.1.8 Buffers and solutions 
Buffer Composition 
PBS 137 mM NaCl, 2.7 mM KCL, 12 mM H2PO4, pH 7.4 
TBS 50 mM Tris, 150 mM NaCl, pH 7.5 
PBS-Tween (PBS-T) PBS + 0.05 % Tween 20 
TBS-Tween (TBS-T) TBS + 0.05 % Tween 20 
 
    Cell culture 
Buffer Composition 
PBS/EDTA PBS + 2 mM EDTA 
MACS Buffer PBS + 2.5 % human albumin + 2 mM EDTA 
FACS Buffer PBS + 2.5 % human albumin + 2 mM EDTA + 0.1 % 
sodium azide 
 
     SDS-PAGE and Western Blot 
Buffer Composition 
Hot lysis buffer 10 mM Tris (pH 8.0), 1 % SDS, 1 mM sodium 
orthovanadate 
SDS sample buffer 0.15 M Tris, 1.2 % (v/v) SDS, 4 mM glycerol, 2 mM β-
mercaptoethanol, 0.02 µM bromophenolblue, pH 6.8 
15 % Resolving gel 15 % (v/v) acryl-bisacrylamid, 0.1 % (w/v) SDS, 25 % 
(v/v) of 1.5 M Tris (pH 8.8), 0.1 % (w/v) ammonium 
persulfate (APS), 0.04 % TEMED 
5 % Stacking gel 5 % (v/v) acryl-bisacrylamid, 0.1 % (w/v) SDS, 12,5 % 
(v/v) of 1.5 M Tris (pH 8.8), 0.1 % (w/v) ammonium 
persulfate (APS), 0.1 % TEMED 
SDS running buffer 2.5 M Tris, 192 mM glycine, 0.1 % (v/v) SDS 
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Blocking solution TBS + 5 % (w/v) BSA 
Transfer buffer 47 mM Tris, 20 % (v/v) methanol, 1.3 mM SDS, 34 mM 
glycine 
Stripping Buffer 2 % (w/v) SDS, 6.3 % of 1 M Tris (pH 6.7), 0.7 % (v/v) β-
mercaptoethanol 
4.1.9 Oligonucleotides 
All human forward and reverse primers were purchased from Metabion. 
Gene Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
hIL6 AGACAGCCACTCACCTCTTCAG TTCTGCCAGTGCCTCTTTGCTG 
hIL8 TTGGCAGCCTTCCTGATTTC TCTTTAGCACTCCTTGGCAAAAC 
hIL1A TGTATGTGACTGCCCAAGATGAAG AGAGGAGGTTGGTCTCACTACC 
hIL1B CCACAGACCTTCCAGGAGAATG GTGCAGTTCAGTGATCGTACAGG 
hTGFβ1 CGGAGTTGTGCGGCAGTGGT GTTGGTGTCCAGGGCTCGGC 
hVEGF-A AGTTCATGGATGTCTATCAGCGC TCCGCATAATCTGCATGGTG 
hMMP1 ATGAAGCAGCCCAGATGTGGAG TGGTCCACATCTGCTCTTGGCA 
hMMP2 CCACTGCCTTCGATACAC GAGCCACTCTCTGGAATCTTAAA 
hMMP9 GCCACTACTGTGCCTTTGAGTC CCCTCAGAGAATCGCCAGTACT 
hMMP3 CACTCACAGACCTGACTCGGTT AAGCAGGATCACAGTTGGCTGG 
hPAI1 GGCCATTACTACGACATCCTG GGTCATGTTGCCTTTCCAGT 
hPAI2 GCTGTTTGGTGAGAAGTCTGCG CTGCACATTCTAGGAAGTCTACTG 
hCXCL1 AGCCAACGTCAAGCATCTCAA AATCCACTTTAGCTTCGGGTCAA 
hCXCL2 GGCAGAAAGCTTGTCTCAACCC CTCCTTCAGGAACAGCCACCAA 
hL1CAM TCGCCCTATGTCCACTACACCT ATCCACAGGGTTCTTCTCTGGG 
hICAM-1 AGCGGCTGACGTGTGCAGTAAT TCTGAGACCTCTGGCTTCGTCA 
hITGβ3 CATGGATTCCAGCAATGTCCTCC TTGAGGCAGGTGGCATTGAAGG 
hCCL2 CCGAGAGGCTGAGACTAAC CTTGCTGCTGGTGATTCTTC 
hCCL7 ACAGAAGGACCACCAGTAGCCA GGTGCTTCATAAAGTCCTGGACC 
hOPN CTGACATCCAGTACCCTGATGC GGCCTTGTATGCACCATTCA 
hGAPDH CGACCACTTTGTCAAGCTCA AGGGGTCTACATGGCAACTG 
 
 
 
40 
 
  
4.1.10 Laboratory Instruments, equipment and materials 
Instrument Commercial Name Company 
Centrifuge  Z233 MK-2 Hermle, Wehingen, Germany 
Centrifuge Rotina 420R Hettich, Tuttlingen, Germany 
Centrifuge Multifuge 3S-R Heraeus, Newport, GB 
Counting chamber Neubauer Improved Neolab Migge, Heidelberg, Germany 
Incubator MCO-20AIC Sanyo, Osaka, Japan 
ELISA plate Nunc MaxiSorp Thermo Fisher, Waltham, MA, USA 
Multiplate ELISA Reader Multiskan EX Thermo Fisher, Waltham, MA, USA 
Luminescence plate CulturPlate-96 Black Perkin Elmer, Waltham, MA, USA 
Luminescence Reader 1450 LSC & 
Luminescence 
Counter 
Perkin Elmer, Waltham, MA, USA 
Gel reader ChemiDoc XRS BIORAD, Hercules, CA, USA 
Microtome SLIDE 2003 Pfm medical, Cologne, Germany 
Flow Cytometer Gallios 4L Beckman Coulter, Sinsheim, 
Germany 
Brightfield microscope Axioskop 40 Zeiss 
Brightfield microscope Leica DM IRB Leica, Wetzlar, Germany 
Fluorescence microscope Leica DM 5500 B Leica, Wetzlar, Germany 
Live cell imaging system IncuCyte® Live-cell 
analysis system 
Sartorius, Goettingen, Germany  
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4.2 Methods 
4.2.1 Patient samples 
Formalin-fixed paraffin-embedded (FFPE) tissue sections from melanoma patients of all 
stages (I-IV) were provided by Prof. Dr. Hassel from the National Center for Tumor Diseases. 
Patient’s written informed consent was obtained prior to sample acquisition and use of 
samples was reviewed by the Ethic Board of the University of Heidelberg (S-091/2011). 
Melanoma samples included primary stage I (n=10), stage II (n=16) and stage III (n=10) 
melanoma specimens, stage III lymph node (LN) metastasis (n=10), and stage IV distant 
metastasis (n=8) samples. In addition, we included healty skin (n=7) as control tissue.  
4.2.2 Immunohistochemistry (IHC) 
Paraffin-embedded samples were cut into sections of 2-5 microns. After rehydration, antigen 
retrieval was performed by boiling the samples for 30 minutes in citrate buffer at pH 6, 
followed by washing in water and blocking with 5 % goat serum for 30 minutes. Blocking was 
done by carefully removing all residual liquid, then encircling the tissue with a hydrophobic 
pen and carefully adding the blocking solution inside the circle. The slides were prepared for 
overnight incubation with the primary antibody as listed in 4.1.6. This was done by removing 
all residual goat serum solution and then adding the antibody, again diluted in blocking 
solution. The next day, the slides were washed in TBS-T and treated with the Dako REAL™ 
Detection System according to the manual. Typically, development with the chromogen 
solution was performed for 5-7 minutes and coloring was monitored under a microscope to 
prevent excessively weak or strong stainings. For single color IHC, the samples were then 
counterstained with Haematoxylin for 15 seconds, then washed under running water and 
embedded in an IHC embedding medium. 
Alternatively, for double color IHC, the AP Red developed slides were blocked for 
endogenous peroxidase activity for 5 minutes with 3% H2O2. Then, the biotin-Streptavidin 
sites from the first reaction were blocked with the Avidin/Biotin Blocking Kit according to 
instructions, followed by overnight incubation with purified anti-slan (DD2) or anti-CD3, as 
described for single color IHC. The slides were washed and the mouse IgM antibody clone 
DD2 was then detected with a goat anti-mouse IgM specific detection system and rabbit anti-
human CD3 with a goat anti-rabbit specific system. The slides were washed in TBS-T and 
green color was developed with the chromogen Histogreen. After this, the cells were shortly 
washed in TBS-T, before haematoxylin counterstain and embedding in xylene-based solution 
was performed.  
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For image analysis, 3 representative images of double stained (slan + CD56) FFPE samples 
were digitalized and the density of cells/mm2 was analyzed and correlated for slanMo and 
CD56+ NK cells. p and r2 values were calculated using linear regression in Graphpad Prism. 
4.2.3 Cell culture methods 
4.2.3.1 Thawing of cells 
Cells were removed from liquid nitrogen storage. The cryovial was disinfected with ethanol 
and placed in a 37 °C waterbath until the content was almost thawed completely. Then, the 
cells were transferred to fresh, pre-warmed culture medium and centrifuged (1300 rpm, 8 
minutes, RT). After resuspension of the cell pellet in pre-warmed medium, the cells were 
transferred to appropriate flasks for culture in the incubator (37 °C, 5 % CO2). 
4.2.3.2 Passaging of cell lines 
Adherent cells in culture were washed with PBS before addition of 1 ml trypsin per 75 cm2 
flask. For trypsin to catalyze adhesion molecule shedding, the flasks were placed at 37 °C 
until cells became round and detached from the plastic through gentle rocking of the flask. 
Trypsin activity was neutralized by addition of sufficient culture medium and transferred to 
tubes for centrifugation (1300 rpm, 8 minutes, RT). Typically, after supernatant removal, the 
cells were then resuspended in 10 ml fresh pre-warmed medium and 1 ml cell solution was 
transferred to a fresh flask, yielding a 1:10 dilution. The dilution factor was adjusted for each 
cell line and current confluency, ranging generally from 1:5 to 1:20. 
Regularly, samples were taken for Mycoplasma contamination tests. 
4.2.3.3 Freezing of cells 
After trypzination, 1 – 5x106 cells in suspension were centrifuged (1300 rpm, 8 minutes, RT) 
and taken up in 1 ml Cryomedium. Then, the cells were immediately transferred to cryovials 
and placed at -80 °C in a freezing container for 1-2 days, before being transferred to liquid 
nitrogen for long-term storage. 
4.2.3.4 Counting of cells by Trypan blue  
Cells in suspension were counted by Neubauer chambers. Therefore, 10 µl cell suspension 
was diluted in trypan blue. The dilution factor was chosen based on the estimated cell 
number, ranging from 1:3 to 1:100. The mixture was then given into a readily prepared 
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Neubauer chamber and cells per area were counted on a 100x magnification. Cell number 
was calculated as follows: 
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 =
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
∗ (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) ∗ 104  
4.2.4 Purification and co-culture of human immune cell 
populations 
4.2.4.1 Density gradient centrifugation 
Peripheral blood mononuclear cells (PBMCs) were isolated in the evening from fresh (< 5 h 
after drawing blood) buffy coats of healthy donors by density gradient centrifugation with 
Biocoll separating solution. The content of the buffy coat was transferred carefully on top of 
15 ml Biocoll and then centrifuged (800 rcf, 25 minutes, RT, without brakes). After 
separation, the intermediate cellular layer was removed and washed 3 times with PBS/EDTA 
(1300 rpm, 11 minutes, 4 °C) and then resuspended in 25 ml cold medium for storage 
overnight on ice. 
4.2.4.2 Isolation of slanMo 
For slanMo isolation on the next day, PBMCs were incubated with diluted M-DC8 hybridoma 
supernatant in MACS buffer in a ratio of 1*108 cells/ml for 15 minutes at 4 °C. After 
incubation, the cells were washed with PBS/EDTA (1300 rpm, 10 minutes, 4 °C) and then 
incubated with rat anti-mouse IgM (1:21 in MACS Buffer and 420 µl per 1*108 cells) at 4 °C 
for 15 minutes. After a second washing step, the cells were resuspended in MACS buffer and 
placed in an AutoMACS for separation with an individual protocol performing positive 
selection. The eluted cells were counted and taken up in fresh complete medium. The purity 
(slan+CD3-) of slan+ cells was determined by FACS staining with an anti-IgM FITC antibody 
targeting the bound hybridoma antibody together with staining for CD3 and CD16. Only 
donors with a purity >90 % were used. The untouched flow through was used for separation 
of other populations. 
4.2.4.3 Isolation of NK cells, CD14+ monocytes, and T cells 
NK cells were isolated with the NK cells isolation kit according to the instructions. However, 
only 75 % of the original volume in the manual was used. A defined fraction of the slanMo 
separation flow through was removed and used for NK cell isolation. The cells were 
separated in an AutoMACS using the ‘Depletes’ configuration for depletion of all non-NK 
cells. Purity (CD56+CD3-) of NK cells was analyzed by FACS and was typically >90 %. 
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CD14+ monocytes were isolated by using the CD14 Microbeads kit according to the vendor’s 
instructions. Separation was performed in an AutoMACS running a positive selection 
protocol. 
T cell isolation was performed with the CD4+ T cell isolation kit according to the instructions. 
Separation was again achieved by running the negative selection protocol ‘Depletes’ on an 
AutoMACS. 
4.2.4.4 Co-culture of different immune cell populations 
For cytokine testing or conditioned medium (CM) generation, co-cultures of (1) slanMo + NK 
cells; (2) CD14+ monocytes + NK cells; (3) slanMo + T cells; and (4) CD14+ monocytes + T 
cells, and mono-cultures of all cell types, were prepared in complete medium. 6 hours after 
initial seeding of the first immune cell population, each culture setup was either stimulated 
with 1 µg/ml R848 or 100 ng/ml LPS, or left unstimulated. 
For both mono- and co-cultures, slanMo and CD14+ monocytes were both seeded at t=0 h 
with a density of 3x105 cells/cm2 and a concentration of 0,5x106 cells/ml, whereas NK cells 
and T cells were seeded concomitant with either R848 or LPS stimulation at t=6 h, both with 
a density of 6x105 cells/cm2 and a concentration of 1x106 cells/ml. This yielded a 1:2 ratio of 
slanMo/CD14+ monocytes to NK cells/T cells. 
At t=24 h, the medium was transferred to tubes and centrifuged (2000 rpm, 12 minutes, 4 
°C). Then, the cell-free supernatant was removed and either used directly or stored at -80 °C.  
4.2.5 Fluorescence-activated cell sorting (FACS) 
For fluorescence staining of suspension cells, 1*105 - 2*105 cells were transferred to a 96-
well V-bottom plate and washed with ice-cold FACS buffer (1300 rpm, 5 minutes, 4 °C). 
Then, the cells were incubated for 30 minutes at 4 °C in the dark with a primary antibody 
mixture diluted in FACS buffer. If necessary, a secondary antibody incubation step was 
performed for unlabeled primary antibodies under the same conditions as for the first 
incubation period. The cells were washed again and transferred in FACS buffer into FACS 
tubes for analysis on a Beckman Coulter Gallios™ or a BD FACS Canto™. Shortly prior to 
measurement, 2 µl 7-AAD was added to each tube for live/dead discrimination. 
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4.2.6 Cytokine-measurement assays 
4.2.6.1 Enzyme-linked immunosorbent assay (ELISA) 
For measurement of TNF-α and IFN-γ concentrations in slanMo/NK cell co-culture CM, the 
supernatants were analysed by ELISA. In an ELISA, plate bound capture antibodies bind to 
their targets in the samples and are then visualized via detection antibodies targeting a 
different epitope.  
4.2.6.2 Flow cytometry based cytokine measurement 
Multi-analyte measurements were performed with LEGENDplex™ kits for flow cytometry 
according to the instructions provided by the vendor. Here, cytokine concentrations are 
determined with a mixture of pre-labeled beads coupled to cytokine-specific antibodies. 
Bound cytokines are then detected with a detection antibody mix, which is subsequently 
fluorescently labeled. The individual fluorescence signal can then be determined for each 
bead type. Flow cytometry analysis was performed on a Gallios™ FACS. 
4.2.7 Migration assays 
4.2.7.1 Neuro probe migration assay 
For quantifying NK cell migration in 96-well scale, 1-day cultured NK cells were adjusted to a 
concentration of 2*106 cells/ml. Conditioned medium from R848-activated slanMo (slanMo 
CM) was provided as chemoattractant in the bottom well of the 96-well plate. In some 
conditions, a CCR5 or IL-8 neutralizing antibody was added directly to the slanMo CM in a 
concentration of 20 µg/ml. Then, a second layer providing a porous support for every well 
was mounted on top. The NK cell solution was added as a drop on each well in a way that 
both liquid phases are connected. The plate was incubated for 2.5 hours in an incubator at 
37 °C and 5 % CO2 to allow for NK cells to migrate. Then, the cells were transferred to a 
luminescence plate and total ATP content was measured with the Cell Titer Glo 
Luminescenct cell viability assay in a black culture plate, optimized for luminescence signal 
detection. In order to calculate exact cell numbers, a standard curve was generated by 
providing defined numbers of NK cells in the measurement plate. Specific migration was 
defined as: 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 (%) = (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 [𝑠𝑎𝑚𝑝𝑙𝑒] − 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 [𝑐𝑜𝑛𝑡𝑟𝑜𝑙]
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 [𝑖𝑛𝑝𝑢𝑡]
) ∗ 100 
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4.2.7.2 Transwell migration assay 
Alternatively to a 96-well format, NK cell migration was also tested with regard to changes in 
chemokine receptor expression. To this end, NK cells were used in a 24-well permeable 
support assay. Again, IL-8 in the slanMo CM was neutralized or not with an anti-IL-8 antibody 
(10 µg/ml) or the respective isotype control. The slanMo CM was provided as bottom 
chamber chemoattractant. As positive control, recombinant IL-8 (100 ng/ml) was used. Then, 
2*105 NK cells in 100 µl volume were carefully added on top of the porous insert, thereby 
connecting the top NK cells with the bottom chamber solution. After 4 hours incubation at 37 
°C and 5 % CO2, the migrated NK cells from the bottom chamber were removed and then 
stained for CXCR1 and CXCR2. Samples were then analyzed on a Gallios™ FACS. 
4.2.8 Conditioned medium (CM) or cytokine treatment of 
melanoma cells 
4.2.8.1 In vitro assay for multiple cell lines 
SK-Mel-28, Ma-Mel-86b, SK-Mel-25, and SK-Mel-30 were seeded in appropriate plates at a 
density of 1x104 cells/cm2 and 3,125x104 cells/ml in medium (5 % FCS only). After a brief 
settlement and initial attachment phase at RT, the recombinant cytokines (50 ng/ml TNF-α + 
500 ng/ml IFN-γ) were added in 1/5 of the cell suspension volume, thereby yielding a final 
concentration of 10 ng/ml TNF-α + 100 ng/ml IFN-γ and a final concentration of 2,5*104 
cells/ml. When the cells grown in unmodified control medium reached ~90 % confluency, all 
samples were trypsinized, washed, counted and reseeded equally at a concentration of 2*104 
cells/cm2 in fresh culture plates and fresh medium. This was repeated for up to 3 passages 
and growth curves were calculated by projecting future growth of the initially seeded 
population. 
4.2.8.2 Standardized SK-Mel-28 CM Treatment 
SK-Mel-28 were seeded at a density of 1x104 cells/cm2 and 3,125x104 cells/ml in 6, 12, 24 
well plates, or 55 cm2 culture dishes in medium (5 % FCS only). After a brief settlement and 
attachment phase at room temperature, the CM or recombinant cytokines (50 ng/ml TNF-α + 
500 ng/ml IFN-γ) were added in 1/5 of the cell suspension volume, thereby yielding a 1 to 5 
dilution and a final concentration of 10 ng/ml TNF-α + 100 ng/ml IFN-γ in a final density of 
2,5*104 cells/ml. The CM was used diluted in order to reduce potential growth inhibiting 
effects stemming from already exhausted co-culture medium. In order to prevent premature 
confluency of the control cultures during the passages, the overall growth conditions were 
limited by using RPMI containing 5 % instead of 10 % FCS. For neutralizing experiments, 
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both anti-human TNF-α (Adalimumab, 50 µg/ml) and anti-human IFN-γ (50 µg/ml) were 
directly added to the CM prior to addition to the respective wells, yielding a final 
concentration of 10 µg/ml each. The cells were then cultured for 4 days at 37 °C, 5 % CO2 in 
an incubator. At the first passage, control cells were typically confluent. For passaging, cells 
were trypsinized, counted, and then reseeded in fresh medium (5 % FCS) at a density of 
1*104 cells/cm2 for cell number analysis after 8 days. Alternatively, the cells were seeded at 
2*104 cells/cm2 and 4*104 cells/ml in appropriate plates for downstream analysis. 
At day 8, the cells were again trypsinized and counted in order to calculate growth curves. 
4.2.8.3 3H Thymidine incorporation assay 
For measuring proliferation via radioactive 3H Thymidine incorporation, SK-Mel-28 were 
treated with CM as described before (chapter 4.2.7.2). 1 day after reseeding in 96 well 
plates, the adherent cells were pulsed for 12 hours with 3H Thymidine (1:5 diluted in medium) 
solution. After the incubation period, the adherent cells were thoroughly trypsinized and 
transferred to a 96-well format membrane Filtermat. In detail, the filter was adjusted in the 
vacuum pump device and washed 3x with water. Then, the soluble cell suspension was 
sucked through and the filter was again washed 3x with water. Then, filter was dried in a dry 
oven at 60 °C for 1 hour. The dry filtermat was sealed in a plastic bag after addition of 
Betaplate Scint Solution. The fully sealed filtermat was then measured for luminescence 
signal in a luminescence reader. The time for each well was set to 1 second. 
4.2.8.4 Senescence-associated β-Galactosidase (SA β-Gal) assay 
SA β-Gal staining was performed on SK-Mel-28 cells reseeded in 48 well plates for 1 day 
after CM treatment (chapter 4.2.7.2). Adherent cells were washed with PBS and then stained 
with the SA β-Gal staining kit by following the manufacturer’s instructions. After overnight 
staining, the staining solution was removed and the wells were filled with 70% Glycerol for 
preservation. The plates were stored at 4 °C in a fridge for later imaging. 
4.2.8.5 Quantification of SA β-Gal positive cells 
For Image acquisition, three representative 100x images were taken. The unmodified images 
were loaded in ImageJ software and total cells were counted manually with cell counter plug-
in. Then, a color threshold encompassing the green/cyan SA β-Gal staining was applied and 
particles (> 40-60 pixel) were counted as positive cells. 
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4.2.8.6 Incucyte time kinetic  
To visualize the kinetics of morphological changes and apoptosis occurring in SK-Mel-28 
during the 4 days exposure to CM, we used the IncuCyte® Live cell analysis system in 
combination with an Annexin V dye to visualize apoptotic cells. Therefore, SK-Mel-28 were 
treated and seeded as described before in flat-bottom 96 well plates in triplicates. After 
addition of CM +/- neutralizing antibodies, IncuCyte® Annexin V Red reagent was added to 
each well according to the manual and the plate was placed in the Incucyte inside an 
incubator at 37 °C, 5 % CO2. Images were taken every two hours for a total of 96 hours with 
a total magnification of 100x and 4 images per well. Data analysis was performed with 
Incucyte software. 
4.2.9 Immunofluorescence (IF) 
4.2.9.1 IF staining 
For p21 and Ki67 IF staining, CM-treated and TNF-α/IFN-γ neutralized melanoma cells were 
seeded on 8 well glass diagnostic slides at 2x104 cells/cm2 covered in a drop of medium. 
After 1 day of culture that allowed the cells to adhere to the glass slide, the slide was 
carefully washed by removing the liquid drop with a vacuum pump and then adding PBS-T. 
The cells were fixed with 4% PFA for 20 minutes at RT and then permeabilized with 0,1 % 
(w/v) Triton-X 100 for 10 minutes at RT. Incubation with primary antibody was performed 
overnight at 4 °C. Either p21 was stained separately or together together with Ki67 and 
diluted as listed in table 4.1.6. The next day, the slide was washed again and incubated with 
secondary antibody g-a-m for Ki67 and g-a-rb for p21 for 30 minutes at RT in the dark. In 
general, after secondary antibody labeling, the slides were kept as dark as possible to 
prevent fluorophor bleaching. The slides were washed and incubated for 5 minutes with 
DAPI diluted 1:20000 in DI water at RT. After nuclear staining with DAPI, the cells were 
washed with DI water, mounted in IF mounting medium and then stored at 4 °C in the dark 
until images were taken.  
4.2.9.2 Digital quantification 
Image acquisition was standardized in a way that the same exposure and settings were used 
for all images from one experiment, allowing to compare fluorescence intensities and number 
of positive cells between conditions. p21 and Ki67 positive cells were quantified digitally with 
the software ImageJ. Therefore, unmodified images were loaded and a threshold intensity for 
each channel separately was defined, including DAPI for quantifying total cells. Then, the 
threshold was applied and particles (> 20 pixel) in each channel were quantified. 
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4.2.10 Western Blot 
For Western Blot analysis of p21 expression, cells taken from CM or cytokine treatment 
experiments were lysed in hot lysis buffer. In detail, hot lysis buffer was pre-heated at 100 °C 
in a thermo block. The cells were washed with PBS, centrifuged (1300 rpm, 8 minutes, 4 °C) 
and then resuspended in boiling hot lysis buffer (1 ml per 5*106 cells). The mixture was 
boiled in a thermo block for 15 minutes with regular mixing of the suspension and then 
centrifuged (14000 rpm, 15 minutes, 4 °C). Afterwards, the supernatant was transferred to 
fresh tubes without disturbing the white smear in the bottom. The protein concentration was 
determined by BCA assay according to the instructions and the samples were stored at         
-20 °C until application in Western Blot analysis. 
For size-separation of proteins in the lysates, the protein samples were diluted in SDS buffer 
and run on a 15 % SDS gel. Then, the proteins were further transferred to a 0.2 µm pore-size 
nitrocellulose membrane. For the transfer of proteins by western blotting, the membrane was 
pre-activated with pure methanol and then placed on top of three Whatman paper pre-
soaked in blotting buffer, followed by the SDS gel and covered again with three soaked 
Whatman paper. Blotting was performed for 1 h at 100 mA, after which the membrane was 
quickly rinsed in TBS-T and then blocken in 5 % BSA for 1 h at RT. The primary antibody 
p21 was added and the membrane was sealed in a plastic foil and incubated overnight on a 
shaking table at 4 °C. The next day, the membrane was washed 3x 5 minutes in TBS-T and 
then incubated with the HRP-labeled secondary antibody diluted in TBS-T for 1 hour at RT. 
After washing, the membrane was developed by addition of HRP substrate in the form of a 
1:1 mixture of ECL reagent and chemiluminescent signals were detected in a 
chemiluminescence imager. In order to quantify protein content, the membrane was 
incubated in stripping buffer for 30 minutes at 56 °C to remove previously bound antibodies. 
A directly HRP-labelel β-actin antibody was used as housekeeping marker and incubated for 
2 hours at RT. Then, ECL signal was again detected as described before. Signal intensity 
was quantified using ImageJ. 
4.2.11 Quantitative polymerase chain reaction (qPCR) 
qPCR experiments were performed by Lenka Kyiacova in Mannheim:  
Total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific), following 
manufacturers’ instructions. RNA was treated with RNase-free DNase I, followed by EDTA 
deactivation for 10 min at 65°C (both from Thermo Fisher Scientific). First strand cDNA was 
synthesized from 2000 ng of total RNA with random hexamer primers, using dNTP mix and 
RevertAid H Minus Reverse transcriptase (all from Thermo Fisher Scientific). qRT-PCR was 
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performed in a Stratagene Mx3500P qPCR machine (Agilent) using SYBR Select Master Mix 
containing SYBR GreenE dye (Applied Biosystems). The relative quantity of cDNA was 
estimated using the ΔΔCT method and data were normalized to GAPDH as housekeeping 
gene. 
4.2.12 Statistical analysis 
All Data were analyzed in GraphPad Prism 5 and are presented as mean ±SEM. Heatmaps 
were created in GraphPad Prism 7. Statistical significance was evaluated by p values, which 
were assessed using 1 way Anova with Bonferroni’s multiple comparison post hoc test for 
groups of 3 and paired t test for groups of 2, unless otherwise indicated. *p<0.05, **p<0.01, 
***p<0.001. 
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5 Results 
5.1 slanMo and NK cells infiltrate human melanoma 
Malignant melanoma is strongly infiltrated by immune cells. With extensive data being 
present on T cell infiltration into melanoma, rather little is known about infiltration of minor 
innate immune cell subsets. In particular subsets capable of initiating immune responses and 
maintaining a pro-inflammatory environment are important for effective anti-tumor responses.  
5.1.1 slan+ and CD56+ cells can be detected in primary and 
metastatic melanoma 
We hypothesized a contribution of the slanMo/NK cell crosstalk in anti-melanoma immune 
responses and therefore aimed at gaining a comprehensive overview of slanMo and NK cell 
infiltration in melanoma. We collected formalin-fixed parafin embedded (FFPE) samples from 
all four stages of melanoma development. Detection of slanMo in tissues is facilitated by the 
monoclonal antibody DD2 that specifically targets the slan antigen and also allows staining of 
FFPE material (Fig. 5.1 A). NK cells were detected by staining for CD56 (NCAM) (Fig. 5.1 B). 
Morphologically, slan+ cells exhibited a monocytic-like shape, yet defined cell populations 
also displayed a DC-like or macrophage-like morphology (Fig. 5.1 A). Interestingly, the lumen 
of vessels often stained positive for slan and individual slan positive cells appeared to be 
lining vessel walls repeatedly (data not shown). CD56 staining consistently identified a 
population of small and round infiltrating cells, consistent with a lymphocytic morphology 
(Fig. 5.1 B). However, CD56 staining intensity was often weak, suggesting the presence of 
CD56dim NK cells in the tissues. When investigating melanoma samples ranging from 
cutaneous stage I, stage II, and stage III melanoma lesions to stage III lymph node and stage 
IV distant metastasis, we could detect slan+ (Fig. 5.1 C) and CD56+ (Fig. 5.1 D) cells over all 
stages of melanoma development. In contrast, both mouse IgM (mIgM) and mouse IgG 
(mIgG), isotypes for DD2 and anti-CD56 antibody, respectively, were negative (Fig. 5.1 E, F). 
Individual stage I, stage II, and stage III samples consistently contained both slan+ and 
CD56+ cells. Distant metastasis samples from stage IV melanoma patients were however 
repeatedly devoid of both cell types. 
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Figure legend on next page.  
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Figure 5.1 – Detection of slanMo and NK cells in melanoma samples. FFPE samples from 
melanoma patients were incubated with the (A, C) anti-slan monoclonal antibody DD2 (slan) or with 
an (B, D) anti-CD56 monoclonal antibody (CD56). (A-B) Representative sections from melanoma 
patients showing morphological features of slan+ and CD56+ cells. Original magnification 200x and 
630x. (C-D) Depicted are melanoma samples including stage I (I), stage II (II), stage III (III) cutaneous 
melanoma, stage III lymph node metastases (III LN), and stage IV distant metastases (IV). Isotype 
staining with (E) mouse IgM (mIgM; isotype for slan staining) and (F) mouse IgG (mIgG; isotype for 
CD56) was performed. An alkaline phosphatase detection system was in combination with a 
chromogen generating a red color was used for detection of positive cells in the samples. (C-F) 
Original magnification of the first and third column is 100x and of the second and fourth is 400x. 
5.1.2 Frequency and correlation of slanMo and NK cells over all 
stages of melanoma development 
Since slanMo and NK cells can enter a synergistic crosstalk facilitating slanMo maturation, 
cytokine production, and NK cell anti-tumor functions, we investigated whether we can also 
observe a co-localization of slanMo and NK cells in melanoma tissue. Therefore, we 
established a two-color IHC system that allows us to detect slanMo and NK cells together 
with the histological information provided by immunohistochemistry but not 
immunofluorescence. Using the NK cell marker CD56 in combination with slan in a two-color 
IHC system does not allow to differentiate between CD56+ NK cells and CD56+CD3+ NK T 
cells. However, co-staining of CD56 with CD3 showed that the vast majority of CD56+ cells 
were CD3 negative and therefore not NK T cells (Fig. 5.2 A). We were also taking into 
account that melanoma cells can stain positive for CD56. However, it was feasible to 
differentiate between CD56+/dim tumor cells and CD56+ immune cells based on general 
morphology and size dicrimination (Fig. 5.2 B). Together, this allowed us to specifically 
identify NK cells by CD56 staining in tissues. Furthermore, slanMo and NK cells exhibited 
similar morphological features when comparing single color staining (Fig. 5.1) with the 
CD56/slan two-color IHC system (Fig. 5.2 C). As expected, slanMo often acquired a larger, 
macrophage-like morphology (Fig. 5.2 D left image), whereas CD56+ cells appeared 
lymphocytic (Fig. 5.2 D right image). 
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Figure 5.2 – Verification of CD56+ NK cell staining in a two-color IHC system. A two-color IHC 
system was established by using first a red-color detection system in combination with subsequent 
detection of mIgM or rabbit IgG with a green detection system. (A) CD56 was co-stained with CD3 in 
order to differentiate CD56+ NK cells from CD56+CD3+ double positive NK T cells on FFPE lymph 
node tissue. Original magnification: left (200x), right (630x). (B) CD56 was co-stained with slan in a 
weak CD56 positive stage III lymph node metastasis melanoma sample. Original magnification: left 
(100x), right (200x). (C-D) Representative images of stage III lymph node metastasis samples of slan+ 
and CD56+ cells as detected in the two-color IHC system. Original magnification: (C) left image 
(200x), right (630x), (D) (630x). 
We then collected a larger panel of melanoma samples again covering all four clinical stages 
for two-color IHC staining. In total, we accumulated 10 stage I (Fig. 5.3 A), 16 stage II 
(Fig. 5.3 B), 10 stage III (Fig. 5.3 C), 10 stage III lymph node metastasis (Fig. 5.3 D), and 8 
stage IV distant metastasis samples (Fig. 5.3 E). We inlcuded healthy human skin samples 
from 7 donors as control tissues (Fig. 5.3 F). When quantifying the number of slanMo for all 
stages, we observed a strong accumulation of slanMo in stage I melanoma lesions, which 
then dropped heavily in stage II and remained constant over the rest of disease progression 
(Fig. 5.3 G). On the other hand, NK cells were detected in very low numbers in stages I and 
II, but increased in frequency in stage III. In comparison, healthy human skin was virtually 
void of NK cells and contained only sparse, isolated slanMo, arguing that the high numbers 
of slanMo and of NK cells in cutaneous tumors and metastasis is due to anti-tumor immune 
responses and active infiltration (Fig. 5.3 H). We observed similar numbers of slanMo and 
NK cells in stage III lymph node metastasis compared to cutaneous stage III melanoma. In 
stage IV distant metastasis, including the skin, lung, and liver as metastatic sites, both 
slanMo and NK cells were rare. Interestingly, we found a significant correlation for slanMo 
and NK cell numbers in stage III melanoma samples (Fig. 5.3 A-F). An explanation for this 
could be provided by a migration mechanism, in which slanMo attract NK cells towards 
advanced melanoma metastasis. Interestingly, this would be in line with the observations of 
high slanMo density in melanoma stage I and increasing NK cell numbers in later stages.  
 
55 
 
  
 
Figure 5.3 – Frequency and correlation of slanMo and NK cells infiltrating melanoma. FFPE 
melanoma samples from representative stage I (A), stage II (B), stage III (C), stage III lymph node 
metastases (D), and stage IV distant metastases (E) were double stained for slan (green) and CD56 
(red). Healthy skin samples were included controls (F). Original magnifications: left column (100x), 
middle column (200x), right column (630x). Graphs on the right depict the correlation of frequencies in 
cells/mm2 correlated for slan and CD56 seperately for (A) – (F). (G) Frequencies of slan+ and CD56+ 
cells/mm2 as depicted in (A) – (E). (H) Frequencies of slan+ and CD56+ cells/mm2 as depicted (F). 
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Taken together, we discovered that slanMo and NK cells strongly accumulate in melanoma 
lesional skin. Additionally, we observed a correlation of slanMo and NK cell infiltration in 
stage III lesions. This could suggest a connected migration mechanism for slanMo and NK 
cells. 
5.2 slanMo recruit NK cells via IL-8 
5.2.1 Characterization of the slanMo chemokine milieu 
The finding that slanMo were present at increased numbers in early stages of melanoma and 
that slanMo and NK cell infiltration correlated in advanced stages of melanoma lead us to 
study whether slanMo are capable of instructing recruitment of NK cells into tissues. To get a 
first overview of the chemokine production of slanMo, we performed multiplex chemokine 
screens of cell-free supernatants from non-activated and TLR 7/8 (R848)-activated slanMo. 
slanMo require a maturation phase that starts after initial settling on culture plates. 
Interestingly, slanMo are not capable of producing IL-12 if stimulated directly after seeding, 
whilst they produce high level IL-12 when stimulated 6 hours after seeding. Since we aimed 
at detecting maximum chemokine levels, we kept the 6 hour maturation phase protocol 
(Fig. 5.4 A). Thus, slanMo were stimulated with 1 µg/ml R848 6 hours after seeding and the 
resulting slanMo conditioned medium (CM) was harvested after a total culture of 24 hours. 
We then analyzed the cell-free supernatants for expression of different chemokines 
(Fig. 5.4 B). The heat map in Fig. 5.4 B displays strong expression of CXCL8 (IL-8) and 
intermediate expression of CCL3 and CCL4, all of which are upregulated after TLR 7/8 
stimulation with R848 (Fig. 5.4 C). We then tested whether NK cells can migrate towards the 
respective ligands discovered in the chemokine screen. By using a 5 µm pore size migration 
system where we provided recombinant CCL3, CCL4, IL-8, and SDF-1 (CXCL-12) in the 
bottom chamber (Fig. 5.4 D), we observed concentration-dependent specific NK cell 
migration for IL-8, whereas CCL3 and CCL4 only induced minor NK cell migration 
(Fig. 5.4 E). SDF-1 was used as a positive control chemoattractant and accordingly yielded 
the highest frequencies of migrating NK cells. 
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Figure 5.4 – Chemokines secreted by activated slanMo recruit NK cells. (A) Time scheme for 
slanMo culture and cell-free supernatant generation. (B) Heat map depicting concentrations of 
chemokines analyzed in the multiplex chemokine screen in slanMo-derived cell-free supernatants with 
and without stimulation with 1 µg/ml R848 from five healthy donors. (C) Graph showing concentrations 
of CCL3, CCL4, and IL-8 from individual donors. (D) Scheme of the experimental setup for NK cell 
migration towards recombinant chemokines. (E) Percentage of NK cells that migrated (substracted of 
medium control values) towards different concentrations of CCL3, CCL4, IL-8, and SDF-1 (CXCL-12). 
SDF-1 was used as positive control. 
5.2.2 Mechanism of slanMo-mediated NK cell attraction 
Based on the observation of directed NK cell migration towards chemokines present in the 
activated slanMo CM, we hypothesized that the slanMo supernatant alone can attract NK 
cells. Importantly, NK cells are reported to express the respective receptors binding to 
CCL3/CCL4 (CCR5) and IL-8 (CXCR1/CXCR2) 105. We provided activated slanMo CM in the 
bottom chamber and seeded NK cells on a porous membrane, as described before. To 
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investigate the relevance of CXCR1/CXCR2 – IL-8 and CCR5 – CCL3/CCL4 signaling, we 
added neutralizing antibodies either against IL-8 or against CCR5, or respective isotype 
controls, directly to the supernatant (Fig. 5.5 A). NK cells showed a strong specific migration 
(9,0 % of total input cells normalized to control) towards slanMo CM, which was not affected 
by the presence of isotype control antibodies (Fig. 5.5 B, C and data not shown). 
Interestingly, when we neutralized IL-8, this effect was abolished and migration was almost 
at baseline level (Fig. 5.5 B). In contrast, neutralization of CCR5 had no significant impact on 
NK cell migration (Fig. 5.5 C). Together, this strongly argues for an essential function of IL-8 
in inducing slanMo-mediated NK cell migration. 
 
Figure 5.5 – NK cell migration towards slanMo CM is mediated by IL-8. (A)  Scheme illustrating 
the migration assay for NK cell recruitment towards slanMo conditioned medium (slanMo CM) under 
IL-8 and CCR-5 neutralizaing conditions. (B) Graph depicting percentage of migrated NK cells towards 
slanMo CM with a neutralizaing antibody against IL-8 or respective isotype control. (C) Graph 
depicting percentage of migrated NK cells towards slanMo CM with a neutralizaing antibody against 
CCR5 or respective isotype control. 
IL-8 binds to the chemokine receptors CXCR1 and CXCR2, subsequently mediating 
internalization and directed migration 154, 155. Consistent with previous findings, we found that 
NK cells express CXCR1 and CXCR2 (Fig. 5.6 A). In order to assess which receptors were 
involved in the IL-8 dependent slanMo CM migration mechanism, we investigated receptor 
expression of NK cells harvested after migration under IL-8 neutralizing and isotype 
conditions, as illustrated in Figure 5.5 B. We observed that NK cells migrating in the medium 
control well were still expressing high levels of both CXCR1 and CXCR2 (Fig. 5.5 C). 
However, migration towards slanMo CM significantly reduced expression of both CXCR1 and 
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CXCR2, and IL-8 neutralization in the slanMo CM efficiently prevented receptor 
downregulation (Fig. 5.5 C, D). For CXCR1, receptor downregulation was completely 
negated, whereas CXCR2 still exhibited ~50 % reduced receptor expression, as depicted by 
mean fluorescence intensity values (Fig. 5.5 D). By relying on both quantification of migrated 
cells and receptor engagement, we were able to demonstrate that IL-8 provided by   
TLR 7/8-activated slanMo is capable of recruiting NK cells.  
 
Figure 5.6 NK cell recruitment by slanMo requires CXCR1/CXCR2. (A) FACS staining for CXCR1 
and CXCR2 expression on CD56+CD3- NK cells. Histograms show CXCR1/CXCR2 staining (violet) 
together with respective isotype control staining (gray). (B) Schematic for illustration of receptor 
expression analysis on migrated NK cells.  (C) CXCR1/CXCR2 staining on NK cells that migrated 
towards slanMo CM with a neutralizaing antibody against IL-8 or respective isotype control. (D) Mean 
fluorescence intensity (MFI) values for CXCR1 and CXCR2 FACS plots depicted in (C). 
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5.3 NK cells and slanMo together limit melanoma growth 
5.3.1 Effect of conditioned medium treatment on melanoma cells 
The TME heavily influences tumor cells, both through soluble factors and cellular 
interactions. We therefore investigated whether the cytokine milieu generated by slanMo and 
NK cells in a synergistic crosstalk affects melanoma cells. We incubated SK-Mel-28 
melanoma cells for a period of 3-4 days with co-culture conditioned medium (CM), which was 
harvested from previous co-cultures of R848-stimulated slanMo and NK cells. After this 
culture in CM, the melanoma cells were harvested and cultured at equivalent cell numbers in 
normal medium (Fig. 5.7 A). We observed that melanoma cells initially exposed to co-culture 
CM stopped proliferating and remained in a growth arrest, whereas control cells grew 
exponentially (Fig. 5.7 B, left graph). In contrast, incubation with slanMo or NK cell mono-
culture conditioned medium (slanMo CM or NK cell CM) had only minor or no influence on 
cell growth, respectively, showing that the observed growth arrest is slanMo/NK cell crosstalk 
dependent (Fig. 5.7 B). 
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Figure 5.7 - R848-stimulated co-culture CM arrests melanoma growth. (A) Scheme for melanoma 
cell CM treatment. (B)  Treatment of SK-Mel-28 with conditioned medium (CM) from different sources, 
including CM harvested from slanMo/NK cell co-cultures (co-culture CM), slanMo mono-cultures 
(slanMo CM), and NK cell mono-cultures (NK cell CM), all stimulated with 1 µg/ml R848. 
5.3.2 Identification of factors that induce a melanoma growth 
arrest 
In order to identify the factors in the slanMo/NK cell CM that inhibit melanoma growth, we 
studied its cytokine content by multiplex analysis. To further shed light on the contribution of 
these cells in the TME, we also included other immune cell mono- and co-cultures, including 
CD14+ monocytes as slanMo replacements and T cells as NK cell replacements. We found 
that R848- and LPS-stimulated slanMo strongly upregulate TNF-α, IL-1β, and IL-12. 
Furthermore, the slanMo cultures and the slanMo/NK cell co-cultures were characterized by 
high TNF-α, IFN-γ, and IL-12p70 levels compared to CD14+ monocyte (CD14+ Mo) cultures 
and CD14+ Mo/NK cell co-cultures (Fig. 5.8 A). Interestingly, the slanMo/NK cell co-culture 
yielded higher levels of IFN-γ, TNF-α, and IL-12p70 compared to slanMo/T cell as well as 
CD14+ Mo/T cell co-cultures, highlighting the pro-inflammatory cytokine production of the 
slanMo/NK cell crosstalk. In contrast, NK cells or T cells alone produced only negligible 
cytokine concentrations compared to slanMo and CD14+ Mo (Fig. 5.8 B).  
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Figure 5.8 – Analysis of the cytokine production of slanMo and CD14+ Mo cultured alone or in 
combination with NK cells or T cells. Different combinations of co-cultures and individual respective 
mono-cultures were cultured for 24 h, before cell-free supernatants were harvested. All cultured were 
stimulated 6 hours after seeding either with 1 µg/ml R848, 100 ng/ml LPS, or left unstimulated. Protein 
levels were measured by multiplex analysis based on labeled beads binding to the analytes in the 
supernatant.  
As TNF-α and IFN-γ were expressed at particularly high levels in TLR-activated slanMo/NK 
cell co-cultures, we hypothesized that these cytokines are the major factors mediating the 
strong growth inhibition effect observed with the co-culture but not mono-culture CM. When 
we incubated melanoma cells with recombinant TNF-α + IFN-γ, this efficiently reduced cell 
numbers over several passages in different melanoma cell lines, including SK-Mel-28,      
Ma-Mel-86b, SK-Mel-25, and SK-Mel-30 (Fig. 5.9 A). In order to demonstrate whether TNF-α 
and IFN-γ as major constituents of the co-culture CM mediated the CM treatment growth 
arrest, we added TNF-α + IFN-γ neutralizing antibodies to the initial melanoma culture. 
Therefore, we established an experimental protocol for SK-Mel-28 with a total culture time of 
8 days and a medium exchange after 4 days (Fig. 5.9 B). Neutralization of TNF-α and IFN-γ 
completely abolished the growth arrest and almost restored exponential growth (Fig. 5.9 C). 
Interestingly, the CM induced growth inhibition was even more pronounced than with 
recombinant cytokines (Fig. 5.9 C), suggesting that the median concentrations in the CM 
exceed the experimental concentrations (10 ng/ml TNF-α and 100 ng/ml IFN-γ) or that other 
factors secreted by the slanMo/NK cell crosstalk exacerbate the inhibition. 
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Figure 5.9 – TNF-α and IFN-γ expressed by slanMo and NK cells induce a melanoma cell growth 
arrest. (A) The melanoma cell lines SK-Mel-28, Ma-Mel-86b, SK-Mel-25, and SK-Mel-30 were 
cultured in medium containing recombinant TNF-α and IFN-γ (10 ng/ml and 100 ng/ml, respectively). 
After 4 days, the cells were seeded in fresh medium and cultured for additional three passages. (B) 
Schematic illustrating the experimental procedure for cell growth cytokine neutralization culture 
assays. (C) SK-Mel-28 melanoma cells were cultured for 4 days in diluted co-culture CM together with 
neutralizing antibodies against TNF-α and IFN-γ or respective isotype controls. After 4 days of culture, 
cells were counted and reseeded in fresh medium for prolonged culture, before repeated counting 
after 8 days of total culture time. 
5.3.3 Analysis of proliferative markers in growth arrested 
melanoma cells 
Based on the consistent growth arrest induced by co-culture CM treatment, we were 
interested in quantifying alterations in melanoma cell proliferation. Therefore, we performed 
Ki67 immunofluorescence staining on CM-treated SK-Mel-28 cells reseeded on microscopic 
glass slides (Fig. 5.10 A). Consistent with slower cell growth displayed in growth curves, the 
percentage of Ki67 positive cells was reduced by ~40 % when the cells were cultured in CM 
(Fig. 5.10 B). The same trend was observed when using recombinant TNF-α and IFN-γ 
(Fig. 5.10 C). Similar to previous neutralization experiments, addition of anti-TNF-α/IFN-γ 
antibodies restored normal proliferation (Fig. 5.10 B).  
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Figure 5.10 – CM treatment reduces the fraction of Ki67-positive cells. (A) Illustration of           
SK-Mel-28 treatment for Ki67 IF staining. (B) Representative images of Ki67 IF staining on SK-Mel-28 
cells grown on microscopic glass slides and pre-treated with CM and neutralization against TNF-α and 
IFN-γ as depicted in (A). Positive cells were quantified using Fiji and a fluorescence intensity threshold 
combined with a minimal particle size. Results are depicted in the right graph. (C) SK-Mel-28 cells 
were treated with recombinant TNF-α and IFN-γ (10 ng/ml and 100 ng/ml, respectively) before Ki67 IF 
staining and quantification as described in (B).
We corroborated these results with 3H-Thymidine incorporation as another method to 
quantify proliferation. Therefore, we applied standard CM treatment with TNF-α/IFN-γ 
neutralization, after which the cells were pulsed for 12 hours prior to measurement (Fig. 5.11 
A). This resulted in significantly reduced proliferation after co-culture CM treatment, which 
was successfully prevented by TNF-α/IFN-γ neutralization (Fig. 5.11 B). In contrast, mono-
culture CM from slanMo or NK cells was not sufficient to limit proliferation (Fig. 5.11 C). 
Analogous to cytokine neutralization, addition of recombinant TNF-α + IFN-γ efficiently 
reduced proliferation in several melanoma cell lines (Fig. 5.11 D). In summary, this 
demonstrates that TNF-α and IFN-γ directly affect melanoma cells by reducing the fraction of 
proliferating cells. 
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Figure 5.11 – CM treatment reduces melanoma cell proliferation. (A) Illustration of melanoma cell 
treatment protocol for 3H-Thymidine incorporation assay. SK-Mel-28 cells were treated with (B) R848-
stimulated co-culture CM + TNF-α/IFN-γ neutralization as described in (A) or with (C) R848-stimulated 
slanMo or NK cell mono-culture CM and pulsed for 12 h with 3H-Thymidine. β-radiation counts were 
normalized to control values. (D) Different melanoma cell lines were treated with recombinant TNF-α 
and IFN-γ (10 ng/ml and 100 ng/ml, respectively) and 3H-Thymidine incorporation was measured after 
a 12 h pulse.  
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5.4 Growth arrested melanoma cells exhibit a 
senescence phenotype 
5.4.1 Kinetics of cytokine-induced melanoma cell growth arrest 
In order to further characterize the phenotype of the CM-mediated growth arrest, we placed 
SK-Mel-28 cells during the 4 days treatment phase in a culture device that repeatedly 
acquires images and thereby allows to monitor morphological changes and confluence 
analysis. When we analyzed tumor growth, we observed a higher frequency of Annexin V 
positive apoptotic cells in the CM  and recombinant TNF-α + IFN-γ condition in comparison to 
control medium and TNF-α and IFN-γ neutralization, which might explain a partial drop in 
proliferating cells (Fig. 5.12 A). For both CM and recombinant cytokine treatment, we 
observed slower cell growth and cultures only reached ~ 60 % confluence, in contrast to 
confluent cell densities in medium control and TNF-α/IFN-γ neutralization conditions 
(Fig. 5.12 A, B). Additionally, we observed that CM treatment changed cell morphology and 
resulted in the accumulation of an enlarged and flattened SK-Mel-28 population that often 
appeared multinucleated (Fig. 5.12 A inlet). Those morphological features are reminiscent of 
a senescence phenotype, which is often characterized by the same morphological 
characteristics. This observation offers an additional explanation for the reduced cell growth, 
as the accumulation of senescent cells in our cultures induced by TNF-α + IFN-γ would 
reduce the fraction of proliferating cells and thereby mimic limited overall proliferation. 
67 
 
  
 
Figure 5.12 – CM treatment affects melanoma viability and cell morphology. (A)  SK-Mel-28 cells 
were treated with co-culture CM (CM) + TNF-α/IFN-γ neutralization or recombinant TNF-α/IFN-γ as 
described before. Cell growth was visualized over a culture period of 4 days in a IncuCyte® live cell 
analysis system and images were taken every 2 hours with 100x magnification. An AnnexinV red 
antibody was included in the culture to visualize apoptotic cells. Representative images after 24h, 48 
h, 72 h, and 96 h are depicted. (B) The confluency over time was analyzed by the IncuCyte® Software 
for all conditions. 
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5.4.2 Evaluation of senescence-associated β-galactosidase 
staining 
For demonstrating senescence as a growth inhibiting mechanism in our cultures, we tested 
whether CM treatment induced the expression of senescence-associated β-galactosidase 
(SA β-gal) in SK-Mel-28 cells. SA β-Gal is a common marker for senescent cells that can be 
visualized at pH 6 through its activity to metabolize X-Galactosidase, which ultimately results 
in a green staining inside senescent cells. To this end, we performed CM treatment and 
reseeded the cells in normal medium for 1 day prior to fixation and SA β-gal staining 
(Fig. 5.13 A). We found that SA β-gal positivity increased significantly with CM treatment 
(Fig. 5.13 B). Importantly, TNF-α/IFN-γ neutralization effectively reduced the percentage of 
positive cells, showing that those cytokines are responsible for the observed effect 
(Fig. 5.13 B). When we used mono-culture CM from slanMo, we observed slightly increased 
SA β-gal positive cells, however strikingly less pronounced than for co-culture CM 
(Fig. 5.13 C). In contrast, NK cell CM showed no effect (Fig. 5.13 C). As TNF-α and IFN-γ 
neutralization significantly reduced SA β-gal staining, we were expecting and could 
demonstrate that addition of recombinant TNF-α + IFN-γ resulted in higher cell numbers 
positive for SA β-Gal (Fig. 5.13 D). This suggests that the cytokine cocktail generated from 
co-culturing slanMo and NK cells contains high amounts of TNF-α and IFN-γ that can lead to 
senescence in melanoma cells. 
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Figure 5.13 – SA β-Galactosidase is upregulated after CM treatment.  (A) Schematic depicting the 
protocol for SK-Mel-28 treatment. (B) SK-Mel-28 cells were treated with CM + TNF-α/IFN-γ 
neutralization as described in (A) and cells were stained for SA β-Galactosidase (SA β-Gal) over night. 
SA β-Gal positive cells were quantified with Fiji and percentages are displayed on the right. SK-Mel-28 
cells were treated with (C) R848-stimulated slanMo or NK cell mono-culture CM or with (D) 
recombinant TNF-α + IFN-γ, stained for SA β-Gal, and quantified as described in (B). 
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5.4.3 Molecular markers of cytokine-induced melanoma cell 
senescence 
In order to substantiate the senescent phenotype observed for SK-Mel-28, we analyzed 
expression of p21 (CDKN1A) as a downstream target of p53 (tp53) in the p53 senescence 
pathway. Treating SK-Mel-28 with CM significantly upregulated p21 expression, as visualized 
by Western Blot and densitometric quantification (Fig. 5.14 A). TNF-α and IFN-γ 
neutralization was able to normalize p21 levels (Fig. 5.14 A). Additionally, recombinant    
TNF-α + IFN-γ induced p21 expression in SK-Mel-28, Ma-Mel-86b, SK-Mel-25, and           
SK-Mel-30 (Fig. 5.14 B), indicating that p21 represents a more common regulator of non-
proliferative, senescence states in melanoma cells. 
 
Figure 5.14 – Western Blot analysis of p21 expression after CM and TNFα + IFN-γ treatment. (A) 
SK-Mel-28 cells were treated as described in Figure 5.13 (A) with CM + TNF-α/IFN-γ neutralization. 
After 4 days culture, the cells were lysed and lysates were analyzed for p21 in Western Blot (WB). WB 
was performed by blotting proteins separated via SDS page onto a nitrocellulose membrane and 
incubating the mebrane with an anti-p21 antibody overnight. Band intensity was quantified by using Fiji 
and was normalized to β-actin measured on the same sample. Graph depicting normalized band 
intensity values is shown on the right. (B) Different melanoma cell lines were treated as described in 
Figure 5.13 (A) with recombinant TNF-α + IFN-γ and WB for p21 was performed as stated in (A). 
As p21 is localized in the nucleus where it modulates cell cycle progression, we were 
interested whether we also observe nuclear p21 accumulation under CM treatment 
conditions. Therefore, p21 was stained by immunofluorescence after fixation of CM-treated 
cells grown on microscopic slides. Consistent with western blot data, p21 increased after 
exposure to CM and TNF-α/IFN-γ neutralization reversed p21 positivity (Fig. 5.15 A). In line 
with this, recombinant TNF-α and IFN-γ strongly increased p21 positive cells (Fig. 5.15 B). In 
summary, these data demonstrate that the growth arrest observed in response to our 
crosstalk is a senescence state characterized by high p21 levels. 
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Figure 5.15 – p21 IF staining of CM and TNFα + IFN-γ treated melanoma cells. SK-Mel-28 cells 
were treated as described in Figure 5.10 (A) with (A) CM + TNF-α/IFN-γ neutralization or with (B) 
recombinant TNF-α + IFN-γ. 1 day after reseeding on microscopic glass slides, the cells were fixed 
and stained for p21 in IF. Positive cells were quantified as described in Figure 5.10. 
5.4.4 Characterization of the senescence-associated secretory 
phenotype 
Senescence induction is commonly associated with changes in the cellular secretome, 
termed senescence-associated secretory phenotype (SASP) 156. In order to further 
characterize our observed senescence phenotype, we designed a panel of markers for 
qPCR analysis based on regularly affected genes reported in the literature 156, 157, 158. After 
treatment with co-culture CM, increased expression of relevant SASP factors such as IL-6, 
IL-8, IL-1α, IL-1β was detected on mRNA level (Fig. 5.16 A). Other markers that were 
significantly upregulated included the matrix metalloproteinases (MMPs) 1, 2, 3, 9, the 
serpins PAI-1 and PAI-2, the chemokine family members CXCL1, CXCL2, CCL2 and CCL7, 
the growth factors TGF-β and VEGF-A, and the adhesion protein ICAM-1. Importantly, with 
the exception of CXCL1 and TGF-β, the increase in mRNA levels were prevented by TNF-α 
and IFN-γ neutralization for all markers. 
Besides mRNA expression, we expanded the SASP analysis by measuring protein 
concentrations for IL-6, IL-8, IL-1α, and IL-1β in melanoma cell supernatants after CM 
treatment. In line with the mRNA results, IL-6, IL-8, and IL-1β were significantly upregulated 
after CM exposure, for IL-8 even above the maximal detection limit of the assay (Fig. 5.16 B). 
This effect was reversed or reduced when we added TNF-α/IFN-γ neutralizing antibodies 
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during the CM treatment. IL-1α was expressed at very low levels. However expression was 
still increased by the CM and reverted by neutralization. 
 
Figure 5.16 – mRNA and protein expression levels of a selected set of markers induced by CM  
treatment. (A) SK-Mel-28 cells were treated as described in Figure 5.13 (A) with CM + TNF-α/IFN-γ 
neutralization. After reseeding in fresh medium and an additional culture period of 2 days, the cells 
were lysed in Trizol and the expression of several genes on mRNA level was performed by qPCR. (B) 
SK-Mel-28 cells were treated as described in (A) and the cell-free supernatant was harvested prior to 
cell lysis for multiplex analysis of different soluble factors. For IL-8, concentrations reached the 
maximum threshold of the assay. 
5.4.5 In vivo evidence for senescence in melanoma 
Since we established a role for innate immunity in inducing a p21high melanoma cell 
senescence in an elaborate in vitro system, we were now interested in whether we can also 
find evidence for this phenotype in vivo. Therefore, we stained FFPE melanoma samples for 
p21 in IHC. This resulted in a strong nuclear staining, which was absent in isotype controls 
(Fig. 5.17 A). In general, p21 staining was mostly restricted to melanoma cells, as 
morphologically different immune cells were predominantly p21 negative. However, only a 
fraction of melanoma cells was p21 positive and this was very donor dependent. Additionally, 
the staining intensity observed for p21 positive cells was not homogenous, instead we 
observed the presence of different melanoma cell populations ranging from absent p21 
staining to weak and also very intense p21 expression. 
In order to connect this to innate immunity, we co-stained p21 with slan. slan+ cells infiltrated 
p21 positive areas and were detected in close proximity to p21high melanoma cells 
(Fig. 5.17 B, C). However, no further quantification of slan or CD56 accumulating within p21 
positive melanomas was performed in this study. 
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With the detection of a p21high expressing melanoma cell population in vivo, we strengthened 
the relevance of our finding that melanoma cells can develop a senescent state 
characterized by p21 overexpression.  
 
Figure 5.17 – p21 staining in melanoma patient samples. (A) FFPE samples from a stage II 
melanoma patient were stained with an anti-p21 antibody (left panel) and the respective rabbit IgG 
isotype control (right panel). Original magnification: 1st and 3rd image 100x, 2nd and 4th image 400x.   
(B-C) p21 was double-stained with slan in a stage II FFPE melanoma sample as described in the color 
code above. Original magnifications: left image 400x, right image 630x. 
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6 Discussion 
6.1. slanMo and NK cells infiltrate malignant melanoma 
6.1.1. Prognostive value of innate immune cell infiltration into 
tumors  
The tumor immune microenvironment plays an important role in tumor growth, progression, 
and metastasis. As outlined by the concept of cancer immunosurveillance, tissues are 
constantly screened by immune cells not only for external threats such as pathogens, but 
also for the presence of malignant cancer cells. The process of malignant transformation is 
often accompanied by changes in the respective cells, i.e. the expression of neoantigens that 
enable T cell responses as well as the release of DAMPs and the upregulation of stress-
induced ligands. Together, these mechanisms form the foundation for anti-tumor immune 
responses. NK cells at the site of initial tumor formation recognize transformed cells and lysis 
of individual tumor cells triggers inflammatory processes. DCs internalize tumor antigens and 
migrate to lymph nodes in order to prime antigen specific T cells. During the priming and 
affinity maturation phase required for adaptive immunity, phagocytes control proliferating 
tumor cells. Finally, expanded tumor-specific T cells eliminate the tumor before metastases 
can arise. 
As outlined in 3.1.5, the process described above represents only the first stage of tumor 
immunology and is often followed by a relapse mediated by different escape mechanisms. It 
is assumed that the effectiveness of anti-tumor immune responses highly depends on the 
local immune TME, especially under checkpoint inhibitor therapy. Various recent reports 
have addressed the issue of deciphering the prognostive value of the immune cell 
microenvironment both in murine cancer models as well as in patient tumors 42, 43, 44, 159, 160, 161, 
162, 163, 164. Typically, most analysis focus on characterizing T cells in the TME with regard to 
activation and exhaustion markers, as well as for the presence of antigen-specific T cell 
clones 44, 48. However, also innate immune cell populations numerously infiltrate melanoma 
and other tumor entitites. Our histological analysis revealed a strong infiltration of slanMo in 
early stages of cutaneous melanoma, followed by increased numbers of NK cells in stage III 
cutaneous lesions and lymph node metastasis (Fig. 5.3). NK cell infiltration in stage III 
melanoma was furthermore accompanied by a significant correlation with slanMo infiltration. 
A recent bioinformatic study utilized expression signatures to delineate the relationship 
between specific leukocyte subset and the survival outcomes of patients 42. They described 
75 
 
  
various markers and associated immune cell populations that correlate with favorable or 
adverse effects over 39 malignancies including solid cancers and blood cancers. 
Interestingly, a rare innate immune cell population was associated with the best prognosis 
over all tumor entities: γδ T cells. The most favorable prognostic gene discovered in the 
analysis was KLRB1 (CD161), which is found on T cell subsets and NK cells 165. Another 
factor of positive prognosis were plasma cells (PCs), suggesting a potential relevance for 
tumor-specific antibody responses. Similarly, yet to a lesser extent, NK cells were associated 
with favorable outcome in solid cancers. Interestingly, NK cell and PC signatures correlated 
with regard to positive outcome, arguing for a role of NK cell ADCC in supporting PC-enabled 
antibody-mediated anti-tumor responses. This would be line with the general concept of 
tumor-specific antibodies that function via engagement of NK cells and tumor clearance via 
ADCC 166. 
Apart from broad-scale transcriptomic analysis, NK cells can also be detected by alternative 
methods in tumors, such as histology and flow cytometry. NK cells were previously described 
to be rather absent from primary tumors but to exert anti-metastastatic functions in        
tumor-draining lymph nodes 111, 113, 167, 168, 169. In this regard, our results that demonstrated NK 
cell infiltration in advanced stage cutaneous melanoma inspire more detailed investigation of 
the mechanisms and modulation possibilities of NK cell infiltration into solid tumors. 
However, it needs to be considered that NK cells are often dysfunctional in tumor tissues. In 
this regard, NK cells are reported to be associated with a worse outcome in hepatocellular 
carcinoma 170. Similarly, Carrega et al. and Platonova et al. showed severly reduced 
cytotoxic capabilities of intratumoral NK cells in non-small cell lung cancer patients 103, 171. 
Besides inactivity due to exhaustion in tissues, Balsamo et al. suggested that melanoma 
cells acquire resistence to NK cell mediated killing under conditions that mirror NK cell to 
tumor cell ratios in the TME. The authors argued for increased HLA I expression as well as 
NKG2D ligand downregulation as resistence mechanisms for this phenotype 172. 
Furthermore, NK cells are reported to execute pro-tumorigenic functions by facilitating tumor 
cell epithelial to mesenchymal transistion (EMT), which can support metastasis formation 173. 
On the other hand, EMT can increase susceptibility to NK cell lysis, thereby reducing 
metastatic efficacy 174. Together, this argues for a potential mechanism where NK cells 
modulate the phenotype of tumor cells in a direction that facilitates subsequent elimination. 
Our data are not offering a prognostic follow-up or a description of the activation status of NK 
cells in situ. It is therefore difficult to judge the effectiveness of NK cells infiltrating in late 
stage cutaneous melanoma. Regardless, elucidation of the conditions and specific 
chemokines that guide NK cells to tumors are of high interest. Mechanistic insights open up 
avenues for recruiting NK cells to newly formed tumors or metastasis, where they can exert 
their widely accepted anti-metastatic potential. 
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NK cells are defined by several genes that identify their cellular origin and can therefore be 
studied in broad-scale transcriptomic analyses. The diversity of monocytes and 
macrophages however often cannot be studied adequately. In particular the subset of non-
classical monocytes, that also encompasses slanMo, is usually neglected due to a lack of 
precise gene signatures robustly identifying these cells in tissues. This hampers the broad-
scale transcriptomic investigation of monocyte subsets in tumors. Since also the specific 
marker slan merely represents a carbohydrate modification not exclusively related to a single 
gene, quantification of slanMo in tumors relies on histological stainings. We observed a high 
density of slanMo, particularly in stage I melanoma, which cannot be considered a 
homeostatic cutaneous condition, since healthy skin was virtually devoid of slanMo. These 
results extend previous reports that have described high numbers of slanMo in metastatic 
tumor-draining lymph nodes of carcinoma patients but absence of slanMo in the primary 
tumor 73 . Increased slanMo cell numbers in early melanoma development suggests 
immediate recruitment to the tumor site. This is in line with the reported patrolling function of 
human slanMo as a sub-group of non-classical monocytes 59, 175. Constant monitoring for 
vascular damage allows slanMo to immediately sense any disturbances in the endothelial 
composition that are triggered by tumor initiation. Recently, Headley et al. visualized and 
quantified the arrival of phagocytic immune cells immediately after generation of 
micrometastastes in the lung 176. They found that patrolling monocytes arrive very rapidly and 
concomitant with neutrophils and classical monocytes, despite in lower frequencies 
compared to neutrophils and classical monocytes. Importantly, patrolling monocytes 
remained in the vicinity of tumor sites for a prolonged time, which was not observed for 
neutrophils and classical monocytes. 
In the TME, monocytes can develop into polarized macrophages, either resembling anti-
tumorigenic M1 or pro-tumorigenic M2 macrophages 54, 55. The attempt to translate this 
phenotypic discrimination to slanMo in tissues is difficult due to the fact that no mouse 
homolog exists that would permit functional studies. However, slanMo in tissues were 
previously described as TNF-α producing 66, 73, 75, 177, CD68 positive 58, 73, IL-23 positive 65, 
iNOS positive 65, and actively phagocytosing 72,  suggesting the tendency to develop an    
anti-tumor M1 phenotype after leaving the circulation 178. In accordance with this hypothesis, 
a recent report suggested the coexistence of two separate slanMo tissue phenotypes; a 
macrophage-like CD163hi/CD14hi/CD64hi/CD16hi phenotype and a DC-like 
CD163low/CD14low/CD64low/CD16low phenotype 72. Interestingly, we observed the presence of 
two morphologically distinct slanMo populations in the melanoma biopsies. In line with the 
study by Vermi et al., DD2 stained round, monocytic cells inside or in the vicinity of vessels, 
arguing for ongoing or recent transmigration. Alternatively, DD2 stained cells displaying 
macrophage features or dendritic-like cells (Fig. 5.1) 72. Our histological stainings lacked 
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functional markers such as TNF-α or IL-12, which precludes a characterization of the in situ 
slanMo activation status. However, our in vitro and the previously mentioned preferential M1 
macrophage polarization in tissues suggests also a high inflammatory potential in the 
melanoma microenvironment. 
Interestingly, the correlation of slanMo and NK cell numbers may suggest linked migratory 
mechanisms. Furthermore, when also considering the differential infiltration pattern in stage I 
and II melanoma, this argues for a hypothesis that slanMo, after becoming fully activated in 
the advanced stage TME, aid in NK cell recruitment. However, since we were not 
normalizing the numbers of slanMo and NK cells to the total immune cell infiltrate, it is so far 
difficult to assess whether the correlation is specific for slanMo and NK cells or mirrors 
increased overall leukocyte infiltration. 
6.1.2. Chemokine production by slanMo 
In an attempt to identify the mechanisms behind the correlated slanMo and NK cell 
infiltration, we pursued the hypothesis that slanMo, present in high levels in early tumor 
development, might account for the increasing levels of NK cells in stage III. Besides low to 
intermediate level CCL3 and CCL4 expression, we found that slanMo are prominent 
producers of IL-8 with intermediate steady state scretion and strongly elevated expression 
after R848-stimulation (Fig. 5.4 B, C). This is in contrast to previous studies that reported 
only minor IL-8 as well as CCL3 production 59, 69. However, these studies were not adhering 
to a 6 h maturation phase before stimulation by TLR ligands, which is important for achieving 
efficient slanMo cytokine production. IL-8 binds to the receptors CXCR1 and CXCR2, mostly 
expressed on neutrophils, monocytes, NK cells and CD8 T cells. Neutrophils are often 
considered tumor promoting, which is why IL-8 is repeatedly associated with tumor 
progression 179, 180, 181. Additionally, IL-8 is reported to represent a major melanoma-derived 
factor in the TME, suggesting that IL-8 potentially has direct pro-tumorigenic effects 182, 183 or 
that IL-8 modulates the immune composition towards a immunosuppressive bias by 
recruitment of MDSCs 184, 185. However, since CXCR1 and CXCR2 are also expressed by 
other immune cell subsets typically associated with a positive outcome, such as CD8 T cells 
and NK cells 42, it can be assumed that IL-8 additionally exerts positive functions in the TME. 
Nevertheless, it will be challenging to dissect the positive from the negative effects and to 
find therapies to manipulate the system. 
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6.1.3. Recruitment of NK cells to the TME  
We were able to demonstrate IL-8 dependent migration of NK cells towards activated slanMo 
supernatants, demonstrating that IL-8 can also exert positive functions in the TME by 
recruitment of cytotoxic NK cells. Our results are consistent with the current literature, where 
it is reported that NK cells express CXCR1 and CXCR2 coupled to the ability to migrate 
towards the chemokine IL-8 derived from different sources, i.e. dendritic cells 105, 186. Besides 
IL-8, CCL3 and CCL4 were also present in slanMo supernatants, yet in lower concentrations. 
Despite reports that state expression of CCR5 on CD56bright NK cells 105, we consistently 
detected only around 1 % of NK cells expressing CCR5 (data not shown) and migrating 
towards CCL3 or CCL4 (Fig. 5.4 E). Accordingly, blocking experiments using anti-human 
CCR5 neutralizing antibodies showed only a marginal reduction in migrated NK cells (Fig. 
5.5 C). Together with successful inhibition of NK cell migration with IL-8 neutralization, this 
demonstrates the instrumental role of IL-8 in the slanMo – NK cell migratory axis. We 
corroborated the receptor-ligand interaction by analysis of migrated cells, revealing that 
exposure to the slanMo CM completely removes the receptors from the cell surface. This can 
be explained by receptor internalization as a result of CXCR1 and CXCR2 signaling in NK 
cells, which subsequently leads to receptor internalization 154, 155, 187, 188. However, it needs to 
be demonstrated that the presence of chemotactic factors suffices for active NK cell 
infiltration into melanoma, since another report states that NK cells are absent from 
colorectal cancer despite ample expression of chemokine ligands in the tissue 189. 
Nevertheless, the discovery of novel potential innate migration axis is highly relevant for the 
understanding and initiation of immune responses in tissues. In addition, this recruitment 
hierarchy could further be expanded by the results recently published by Böttcher et al. 190. 
Using a melanoma mouse model, they demonstrated that tumor infiltrating NK cells can 
recruit cDC1 via XCL1 and CCL5. Infiltrated cDC1 then aid in initiating adaptive immune 
responses through recruitment and priming of T cells. In this line of thought, our results argue 
for a mechanism in which slanMo extravasate at the site of newly formed tumors or 
metastasis and recruit NK cells to facilitate influx of cDC1.  
6.2. The slanMo/NK cell crosstalk induces melanoma cell 
senescence 
The role of cellular senescence in tumorigenesis and tumor progression is still a topic of 
debate. While it is widely accepted that senescence is a major tumor suppressor 
mechanisms preventing cell cycling after mutagenesis, the function and the associated 
prognostic relevance of senescence in fully established tumors is controversial. For one, it is 
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unclear whether senescence represents a ultimately irreversible proliferation stop. Similar to 
senescence, tumor dormancy, as it is described during the equilibrium phase (3.1.5.2), is 
potentially characterized by a low proliferative status of the tumor 30. Interestingly, this would 
be in line with the hypothesis that senescence, besides representing a tumor suppressor 
mechanism, can facilitate immune escape through maintenance of individual, temporarily 
non-cycling tumor clones.  
6.2.1. Comparison of different immune cell cytokine profiles 
The tumor immune  microenvironment affects many areas of tumor growth, progression, and 
metastasis 191. Many questions arise when trying to model immune interactions in the TME: 
What immune cells are present? Which type of immune cells co-localize? How is the 
interaction taking place? And what is the prognostic value of this immune crosstalk? Studies 
often rely on histological analysis when trying to pursue these questions, since only 
histological staining combines single-cell identification with spatial information. In line with 
previous reports, we observed co-localization of slanMo and CD56+ NK cells in tumor-
draining lymph nodes of stage III melanoma patients 73. This led us to further characterize the 
slanMo and NK cell crosstalk with regard to their cytokine profile. Cytokines and their effects 
on tumor cells are believed to play a important role in the TME. Similar to the  ramifications 
different immune compositions account for, the effects that different cytokine milieus can 
exert are discussed controversially. For example, while IFN-γ is reported to represent a gene 
that is essential for cancer immunotherapy and tumor clearance 192, there are also studies 
suggesting a contribution to immunoevasion and cancer progression 193. 
Consistent with previous reports, we found that the slanMo/NK cell crosstalk excels at 
producing the proinflammatory cytokines TNF-α, IFN-γ, and IL-12, after stimulation with TLR 
ligands. In contrast, NK cell mono-cultures were not producing meaningful amounts of any of 
the cytokines tested, regardless of TLR-activation. This is not unexpected, since NK cells are 
typically activated by other means such as pro-inflammatory cytokines or stress-induced 
ligands, whereas studies on the potency of TLR activation in NK cells are still not providing 
unambiguous results 194. On the other hand, slanMo are known for high TLR expression, 
which is why we observed similar TNF-α levels after TLR stimulation irrespective of mono- or 
co-culture setup 65, 66. To be able to put this into context with the TME, we included CD14+ 
monocytes and T cells in our experiments. Surprisingly, the slanMo/NK cell crosstalk proved 
to be superior in TNF-α, IFN-γ, and IL-12 production compared to CD14+ monocyte/NK cell 
and slanMo/T cell co-cultures (Fig. 5.9). This is consistent with the previously described 
differential IL-12 producing potential between slanMo and CD14+ Mo, since IL-12 limits NK 
cell IFN-γ production 58. The difference between NK cell and T cell co-cultures with slanMo 
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highlights the role of NK cells as innate source of IFN-γ, because T cells typically require 
additional antigen-specific stimulation to reach full activation 195. 
6.2.2. Supernatants from slanMo/NK cell co-cultures arrest 
melanoma growth 
The cytokine milieu generated by slanMo and NK cells arrested tumor growth over several 
culture passages. We compared the inhibition by TLR activated slanMo and NK cell mono-
culture CM with the activated co-culture CM. Besides slightly reduced melanoma cell growth 
numbers observed with slanMo CM, which might be due to TNF receptor mediated 
apoptosis, we only observed a consistent growth arrest with co-culture CM treatment. 
Together with TNF-α and IFN-γ neutralization experiments, this demonstrated the 
requirement of the slanMo/NK cell crosstalk in order to facilitate synergistic high level IFN-γ 
and TNF-α production capable of limiting melanoma growth. TNF-α/IFN-γ neutralization 
restored exponential growth to around 80 % when considering cell numbers at day 8 after 
seeding. An explanation for this could be provided by insufficient neutralization efficiency. 
However, analogous experiments where TNF-α/IFN-γ neutralizing antibodies were added to 
recombinant TNF-α + IFN-γ resulted in complete restoration of SK-Mel 28 growth rates (data 
not shown), arguing against this as the cause for the incomplete reversal of the CM-induced 
growth inhibition. Another explanation is that additional factors produced in the slanMo/NK 
cell crosstalk influence melanoma cell proliferation or induce apoptosis. Apart from IL-12, for 
which no direct effects on tumor cells are reported, IL-6 and IL-8 are highly expressed by 
slanMo 58 and studies indicated their involvement in senescence 196, 197, 198. It is therefore 
conceivable that IL-6 and IL-8 account for the incomplete growth restoration after CM 
treatment with TNF-α/IFN-γ neutralization. This would also be coherent with the observation 
of reduced cell numbers and increased SA β-Gal positive cells after slanMo mono-culture 
CM treatment (Fig. 5.7 B, Fig. 5.14 C). Another soluble factor typically associated with 
senescence is TGF-β 199, 200. Since neither concentration measurement nor neutralization 
was performed for TGF-β, we cannot completely rule out an additional effect of TGF-β in our 
system. 
The detection of stable cell numbers is not directly indicating a stop in proliferation. Other 
aspects can mimic the effect of stagnant growth curves, i.e. apoptosis of cells. CM treatment 
clearly increased apoptosis rates in SK-Mel-28, as visualized by Annexin V staining 
(Fig. 5.13 A). However, as Ki67 staining and 3H-Thymidine incorporation revealed reduced 
proportions of proliferating cells induced by CM as well as recombinant TNF-α + IFN-γ, it 
appears that both apoptosis and reduced proliferation together result in the virtually complete 
arrest up to day 8. It is difficult to extract and assess the isolated effect of                         
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TNF-α/IFN-γ-mediated growth inhibition without influences stemming from apoptosis. 
However, as also the Ki67 staining revealed, cytokine treatment affects only a fraction of 
melanoma cells, since ~40 % of cells remained in a proliferative state. It is therefore also 
understandable that the growth curves start to resemble exponential growth after several 
passages, since unaffected melanoma cells rapidly outnumber non-proliferating cells. In 
addition, single-cell tracking in kinetic studies revealed that the majority of SK-Mel 28 cells 
were actively dividing. Confluency analysis showed a steady, yet significantly lower increase 
in confluency compared to control conditions. Morphologically, only a minor subpopulation 
appeared remarkable, which was demonstrated by an enlarged and flattenend morphology. 
This morphological appearance is described as  a major feature of senescence, interestingly 
also for the cell line used here, SK-Mel-28 201. It was therefore reasonable to further 
investigate the possibility of senescence as the proliferation-limiting mechanism.  
6.2.3. Phenotype of the senescence induced by the slanMo/NK cell 
crosstalk 
SA β-Gal is repeatedly used to identify senescent cells. We detected significant upregulation 
of SA β-Gal staining in SK-Mel 28 cells after treatment with co-culture CM. By performing 
neutralization experiments and recombinant cytokines, we could trace the effect back to 
TNF-α and IFN-γ. TNF-α and IFN-γ were previously associated with senescence. In detail, 
Braumüller et al. described senescence induction in a β-cell cancer mouse model  that was 
also characterized by elevated SA β-Gal positive cells 123. The senescence effect Braumüller 
et al. investigated was dependent on Th1-derived TNF-α/IFN-γ acting directly on β-cancer 
cells. Additionally, they described reduced in vitro growth of cell lines derived from various 
cancer types, including one melanoma cell line. However, the study lacked a characterization 
of the cytokine induced senescence phenotype in a broader setting including different tumor 
entitites. In this regard, our study in melanoma increases the knowledge about the translation 
of this phenotype to anti-tumor immunity in general. In detail, we expand this concept by two 
important characteristics: (1) we describe an innate immune crosstalk composed of slanMo 
and NK cells as mediators of TNF-α/IFN-γ induced senescence; (2) we discover that the 
slanMo/NK cell crosstalk exclusively upregulated p21 in melanoma cells, suggesting 
activation of the p53/p21 pathway. This was in contrast to the observations made in Th1-
mediated cytokine induced senescence, where senescence was triggered by the 
p16Ink4a/Rb pathway. However, our results are reasonable when considering that 
melanoma cells regularly carry mutations in the CDKN2A locus. p21 acts downstream of 
p53, however, it can also function in an p53-independent manner. Since p53 is commonly 
mutated in melanoma cell lines and in particular in the cell lines SK-Mel-25 and SK-Mel-30 
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used in this study (Broad Institute Cancer Cell Line Encyclopedia), it appears that we 
discovered a novel TNF-α + IFN-γ triggered p53-independent mechanism for p21-mediated 
senescence in melanoma cells. 
Similarly, a recent report stated NK cell-mediated cell cycle arrest of melanoma cells after 
appropriate stimulation with PDGF-DD, which triggered Nkp44 signaling 124. The growth 
arrest was dependent on NK cell derived TNF-α + IFN-γ, however no connection to 
senescence was provided. The concept of NK cell involvement in tumor senescence extends 
NK cell mediated anti-tumor functions, which are most prominently focused on tumor-
directed cytotoxicity. Yet, senescent tumor cells potentially still pose a threat since tumors 
can re-emerge after periods of dormancy. Interestingly, NK cells are known to recognize and 
eliminate senescent cells. This is enabled through expression of stress induced ligands such 
as DNAM-1 ligands or ULBP proteins on the surface of senescent tumor cells 202, 203. 
The concept of cancer stem cells describes individual tumor clones that acquire a stem-cell 
like phenotype, which equips them with increased tumor-initiating potential. In melanoma, 
this was demonstrated by simple serial dilution injection experiments into 
immunocompromised mice, showing that particular subpopulations differ strikingly in their 
ability to establish tumors 204. A recent study described a connection between senescence 
and stemness in a way that senescence facilitates the acquisition of a cancer stem cell 
phenotype, which is  associated with increased aggressiveness and tumorigenic potential 
after relapse 205. Additionally, cancer stem cells are assumed to represent a major cause for 
therapy failure. Due to low cycling and reduction of MHC-I expression, cancer stem cells 
excel at evading destruction by chemotherapy and T cell-mediated immunotherapy, 
respectively 206, 207, 208. In this line of thought, cancer stem cells are also often considered to 
represent a state of tumor dormancy and therefore mediate the escape from the immune 
system during relapse 208, 209. Inflammatory environments in melanoma are reported to lead 
to reversible melanoma cell dedifferentiation associated with modulation of T cell antigens 
210. Similar to recognition of senescent cells, NK cells are reported to preferentially kill stem-
cell like cancer cells 211, 212, 213, 214. This creates an intriguing concept in which NK cells 
facilitate both the generation as well as subsequent clearance of senescenct and stem-like, 
therapy-resistant, tumor clones. However, as demonstrated by the negligible cytokine profile 
of unstimulated NK cells, this requires the presence and adequate activation status of NK 
cells in the TME. Of note, contradictory results were previously published by Stokes et al. 
that described limited clearance of senescent cancer cells mediated by NK cells 215. 
Another interesting link between tumor senescence and NK cells can be drawn with regard to 
chemokine-mediated NK cell recruitment. As will be discussed below, senescence in tumor 
cells is associated with the secretion of an array of cytokines, chemokines, and growth 
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factors. In this regard, it was reported that senescent tumor cells are eliminated by NK cells 
recruited via tumor-derived CCL2 216. Interestingly, there is an additional connection between 
p53 and CCL2 proposed, wherein p53 directly binds to a CCL2 enahncer region and 
regulates gene expression 217. Similarly, CX3CL1, another chemokine that mediates NK cell 
migration, is also suggested to be a target gene of p53 218. Together, these results 
strengthen the previous assumption of NK cells as specialized senescence-targeting cells, as 
senescence induction is accompanied by upregulation of NK cell recruiting factors. 
6.2.4. Functions of the SASP in the TME 
Not only immune cells contribute to the TME cytokine milieu, but also other cellular 
components such as fibroblasts, endothelial cells, and tumor cells majorly shape the 
composition of soluble factors in the microenvironment. We observed increased expression 
of various cytokines generally considered in the literature to represent SASP components 
(Fig. 5.17) 144. Secretion of  inflammatory cytokines such as IL-6, IL-8, IL-1α, and IL-1β have 
the potential to modulate the tumor microenvironment towards anti-tumor immune 
responses, as described for M1 macrophage polarization after exposure to pro-inflammatory 
SASP factors. Consistent with the role of M1 macrophages, this resulted in reduced 
tumorigenesis in a mouse model of liver fibrosis induced hepatocellular carcinoma 219. 
Furthermore, the strong IL-8 upregulation we observed is intriguing when considering an 
additive effect on NK cell recruitment. Nevertheless, chronic inflammation that is induced by 
continuous SASP expression argues for major pro-tumorigenic functions 156, 220. Our 
observation of increased mRNA levels for MMPs also signals pro-tumorigenic and pro-
metastatic activity (Fig. 5.17 A). Active extracellular matrix remodeling is often considered a 
prerequisite of metastasis. In this regard, elevated MMPs might skew melanoma cells 
towards higher metastatic potential, similar to as described for  thyroid cancer cells 221. In 
addition to IL-8, several other chemokines where upregulated in a TNF-α/IFN-γ-dependent 
fashion, including CXCL1, CXCL2, CCL2, and CCL7 (Fig. 5.17 A). The first three 
chemokines argue for increased attraction of CXCR2 expressing cells such as NK cells or 
neutrophils, whereas CCL2 and CCL7 potentially attract CCR2-expressing monocytes to the 
TME. However, it is difficult to predict the in vivo effect on shaping the local immune 
microenvironment. The marginal increase in TGF-β transcripts in contrast to striking pro-
inflammatory cytokine upregulation might suggest a tendency towards anti-tumorigenic 
immune responses in our system. Interestingly, we found upregulation of ICAM-1 transcripts. 
This is coherent with our in vitro observations that CM- and recombinant TNF-α/IFN-γ-treated 
cells required longer times to loosen from culture plates during incubation with trypsin (data 
not shown).  
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With the list of SASP molecules in mind, a current debate focuses on whether the SASP is 
actually beneficial for tumor development or not. The expression of angiogenic and matrix 
modifying enzymes is related to heightened metastatic potential and maintaining chronic 
tumor-promoting inflammation represents a hallmark of tumor biology. On the other hand, 
secretion of chemotactic SASP factors by senescent cells was shown to facilitate NK 
recruitment and clearance of senescent cells 216. Thus it is still difficult to fully assess the 
impact of the SASP in the TME and in tumor progression. In addition, it was postulated that 
the SASP requires continuous DNA-damage response signaling 144 and that isolated 
overexpression of p16 or p21 does not involve secretion of SASP factors 222. This would 
imply that constant DNA-damage occurs through TNF- and IFN-receptor signaling in our 
system, since we observe p21 upregulation co-existing with SASP factor upregulation. 
However, we were not investigating DNA-damage markers in CM-induced senescence and 
thus we cannot rule out the possibility of DNA-damage response signaling. 
All pro- and anti-tumorigenic aspects considered, to be physiologically relevant in limiting 
melanoma progression, cytokine induced senescence should represent a temporary 
condition that provides time for NK cell and cytotoxic T cell mediated tumor clearance. 
6.3. Clinical relevance of patrolling monocytes and NK 
cells in melanoma 
Despite major differences between artificial mouse models and the situation in human 
patients, development of cancer immunotherapeutics typically originates from basic 
research. Hanna et al. described strongly increased metastasis formation in the absence of 
murine patrolling monocytes 53. In their model, patrolling Ly6Clow monocytes extravasated at 
early metastatic sites, ingested tumor material, and contributed to tumor clearance through 
recruitment of NK cells. Together with other reports that focus on the anti-metastatic role of 
the murine patrolling monocyte and NK cell crosstalk, this strenghtens the relevance of 
innate immune responses in tumor immunology 127, 223. However, patrolling monocytes were 
also previously associated with immunesuppressive, even pro-tumorigenic functions related 
to anti-angiogenic therapy 224. Without doubt, unleashing the full synergy of slanMo and NK 
cells in vivo would require adequate stimulation in the TME. 
6.3.1. Evaluation of innate immune cell stimulation in the TME 
Besides manipulation of the immune activation status in the TME by tumor cells, other 
conditions that often render immune cells exhausted and futile include lack of stimulatory 
85 
 
  
factors, hypoxia, and spatial exclusion of immune cells.  Immune-stimulating agents are often 
scarce in developed tumors where little apoptosis and cytotoxicity occurs. Besides NK cells, 
which are well studied regarding recognition of malignant cells, precise mechanisms for 
activation of for example monocytes or DCs in the TME are still not clear. Certain apoptosis 
related molecules are assumed to trigger PRR signaling and thereby activate innate immune 
cells. The nuclear protein HMGB1 is released during cell death but can also be produced by 
other immune cells such as NK cells. Interestingly, besides perforin/granzyme-mediated 
release of tumor cell HMGB1, it was found that NK cells secrete a chemotactic HMGB1 
variant after co-culture with tumor cells. NK cell-derived HMGB1 then recruits additional 
RAGE-expressing NK cells, resulting in amplified NK cell responses 225. Since HMGB1 is 
reported to trigger TLRs and activate monocytes and DCs, tumor- and immune cell-derived 
HMGB1 together has the potential to initiate immune responses in the TME 31. Surprisingly, 
HMGB1 expression in melanoma cells is reported to correlate with poor prognosis in 
patients, despite its pro-inflammatory functions. In detail, Li et al. described senescence 
induction in melanoma cells as a response to HMGB1 suppression by RNA interference 226. 
Constant HMGB1 expression prevented p21 upregulation and maintained a cycling state, 
which was abrogated in the absence of HMGB1. Similarly, HMGB1 is reported as a factor 
secreted by senescent cells and abnormal HMGB1 expression was associated with 
supporting a senescent state 227. In this line of thought, it would be conceivable that NK cells 
further modulate tumor cell senescence through endogenous HMGB1 as well as tumor cell-
derived HMGB1 released through cell lysis.  
Recently, it was stated that tumor-derived exosomes activate patrolling monocytes and 
thereby facilitate immunosurveillance 128. Similar to the function of tumor exosomes in 
modulating and preparing metastatic seeding 228, Plebanek et al. demonstrated that 
successful metastasizing depended on exosome composition, notably the presence of PEDF 
on exosomes. Interestingly, PEDF stimulated patrolling monocytes and expression of PEDF 
was the factor that differentiated metastatic from non-metastatic melanomas. Similarly, PEDF 
was shown to activate human macrophages in vitro, arguing for PEDF as a innate immune 
stimulus in the TME. 
Together, these results outline the potential of innate immune cell activation in TME. 
Ensuring optimal stimulation however might require therapeutic intervention. One option to 
achieve this is by the use of TLR 7/8 ligand therapeutics such as imiquimod, which is studied 
for treatment of cutaneous melanoma lesions and metastasis. Topic imiquimod application 
has been reported to induce melanoma regression and is also investigated for supportive 
treatment after initial melanoma excision 138, 139, 140. Since slanMo express TLR 7 and 8, 
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imiquimod therapy can potentially activate those cells in the TME and thereby initiate a 
senescence-inducing slanMo/NK cell crosstalk.  
6.3.2. Relevance of melanoma cell senescence for cancer therapy 
Senescence in tumors is associated with both pro- and anti-tumorigenic properties. 
Nevertheless, senescent cells are rendered in a unproliferative state that potentially renders 
them susceptible to other treatment options as well as to destruction by NK cells. In this 
regard, current lines of therapeutic inventions aim at disturbing tumor-intrinsic modulation of 
the cell cycle. Most prominently, CDK inhibitors are currently tested for their ability to arrest 
tumor cell growth. Recently, Goel et al. investigated the CDK4/6 inhibitor Ademaciclib in 
different mouse tumor models and found that inhibition of G1 CDKs induced a senescence-
like phenotype 229. Interestingly, CDK4/6 inihbition was associated with increased T cell-
mediated anti-tumor immunity, enabled through increased expression of antigen-presentation 
machinery components. In a similar line of thought, Ruscetti et al. demonstrated senescence 
as a result of combination treatment with MAPK and CDK4/6 inhibitors 230. In this study, 
clearance of senescent cells was found to be dependent on NK cells becoming activated by 
tumor-derived SASP factors. Together, these data suggest that cell cycle proteins offer 
attractive targets for novel therapeutics, in particular for combination therapies with immune 
checkpoint inhibitors and targeted therapies 151. 
6.4. Conclusion 
Innate immune cells are instrumental in anti-tumor responses as first line of defense and 
initiators of adaptive immune responses. Here, we demonstrate the senescence-inducing 
capability of innate immune cells represented by slanMo and NK cells undergoing a 
synergistic crosstalk. We observed correlating numbers of infiltrating slanMo and NK cells in 
stage III melanoma. Furthermore, we provided an explanation for this finding by 
demonstrating that slanMo can recruit NK cells. This migration axis was dependent on 
slanMo-derived IL-8 signaling via CXCR1 and CXCR2 on NK cells. Regarding functional 
aspects of the slanMo/NK cell crosstalk, we showed that the cytokine milieu generated by 
TLR 7/8-activated slanMo and NK cells limits melanoma cell growth characterized by 
reduced cell numbers and reduced proliferation. Mechanistically, we found that the growth 
arrest is mediated by senescence induction in melanoma cells. We validated this by 
demonstrating increased SA β-Gal staining, increased p21 expression, and the secretion of 
SASP factors, together strongly arguing for a senescence phenotype. 
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Figure 6.1 -  Schematic summarizing the actions of the slanMo/NK cell crosstalk in melanoma. 
(1) slanMo become stimulated by TLR ligands in the TME or provided by TLR ligand therapy. (2) 
slanMo produce IL-8/CXCL8 that recruits NK cells to the TME. (3) slanMo and NK cell undergo a 
synergistic crosstalk that yields high levels of IL-12, IFN-γ and TNF-α. (4) slanMo/NK cell crosstalk 
derived TNF-α and IFN-γ can induce a senescence phenotype in melanoma cells. 
Combining the insights gained from this study with recent reports provides a hypothesis for 
the initial contact between newly formed melanoma tumors or metastasis with the innate 
immune system (Fig. 6.1). In detail, we provide evidence for a hierarchical order involving (1) 
strong early infiltration and activation of slanMo followed by (2) subsequent recruitment of NK 
cells. The resulting intratumoral slanMo/NK cell crosstalk (3) generates very high levels of 
TNF-α and IFN-γ that (4) induce senescence in melanoma cells. This order can be extended 
by the mouse model study of Böttcher et al. that described recruitment of T cell-priming 
cDC1 by intratumoral NK cells. Furthermore, our results can potentially be translated to 
checkpoint inhibitor therapy when considering the study by Barry et al. demonstrating that 
the presence of NK cells and cDC1 is a major determinant of checkpoint inhibitor therapy 
responsiveness231. 
Taken together, we broaden the concept of cytokine-induced senescence by including innate 
immune responses. Our results indicate that therapies providing optimal monocyte and DC 
stimulation through TLR 7/8 ligands, such as topical imiquimod treatment, strongly activate 
slanMo present in primary melanoma and metastasis and fuel a slanMo/NK cell synergistic 
crosstalk that reduces tumor progression through TNF-α/ IFN-γ-mediated senescence 
induction. 
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8 Abbreviations 
°C   degree 
µg   microgram 
A488   Alexa Fluor 488 
A647   Alexa Fluor 647 
ADCC   antibody-dependent cellular cytotoxicity 
AP   alkaline phosphatase 
APC   antigen-presenting cell 
BCA   bicinchoninic acid 
Bcl-XL   B-cell lymphoma-extra large 
BCR   B cell receptor 
CCL   CC chemokine ligand 
CCR   CC chemokine receptor 
CD   Cluster of Differentiation 
cDC   conventional dendritic cell 
CDK   cyclin-dependent kinase 
CDKI   CDK inhibitor 
cDNA   complementary DNA 
CLR    C-type lectin-like receptor 
CM   conditioned medium 
cpm   counts per minute 
CTLA-4  cytotoxic T-lymphocyte-associated Protein 4 
CXCL   C-X-C chemokine ligand 
CXCR   C-X-C chemokine receptor 
DAMP   damage-associated molecular pattern 
DC   dendritic cell 
DD1   Dresden 1; monoclonal antibody directed against slan 
DD2   Dresden 2; monoclonal antibody directed against slan 
ECL   electrochemiluminescence 
ECM   extracellular matrix 
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EDTA   ethylenediaminetetraacetic acid 
EMT   epithelial to mesenchymal transition 
FACS   fluorescence-activated cell sorting 
FCS   fetal calf serum 
FFPE   Formalin-fixed paraffin-embedded 
g   gram 
GPCR   g-protein coupled receptor 
HMGB1  high mobility group box 1 
HRP   horseradish peroxidase 
ICAM1   intercellular adhesion molecule 1 
IDO   Indoleamine 2,3-deoxygenase 
IF   Immunofluorescence 
IFNGR1  Interferon gamma receptor 1 
IFN-γ   Interferon gamma 
IgG   Immunoglobulin 
IHC   Immunohistochemistry 
IL   Interleukin 
ILC   Innate lymphoid cell 
Iso   Isotype 
ITAM   immunoreceptor tyrosine-based activation motifs 
ITIM    immunoreceptor tyrosine-based inhibitory motifs 
JAK1/2  Janus kinase 1/2 
KLRB1  Killer Cell Lectin Like Receptor B1 
KLRG1  Killer cell lectin-like receptor subfamily G member 1 
LFA-1   lymphocyte function-associated antigen 1 
LPS   Lipopolysaccharid 
Ly6C   lymphocyte Ag 6C 
MAPK   mitogen-activated protein kinase 
M-DC8  Munich – dendritic cell 8; monoclonal antibody against slan 
MDSC   myeloid-derived suppressor cell 
mg   milligram 
110 
 
  
MHC   major histocompatibility complex 
MIC-A   MHC class I chain-related gene A 
MMP   matrix metalloproteinases 
NF-κB   nuclear factor k-light-chain-enhancer of activated B cells 
ng   nanogram  
NK cell  natural killer cell 
NLR   NOD-like receptor 
NR4A1  nuclear receptor subfamily 4 group A member 1 
OIS   oncogene-induced senescence 
p16   p16INK4a 
p21   p21cip1 
PAMP   pathogen-associated molecular pattern 
PBMCs  peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
pDC   plasmacytoid dencritic cell 
PDGF   platelet-derived growth factor 
PD-L1   Programmed cell death 1 ligand 1 
PEDF   pigment epithelium-derived factor 
pg   picogram 
PLC2   phospholipase Cβ2 
PSGL-1  P-selectin glycoprotein ligand-1 
RAGE   receptor for advanced glycation enproducts 
Rb   Retinoblastom 
rcf   relative centrifugal force 
RLR   RIG-like receptor 
RPMI 1640  Roswell Park Memorial Institute 1630 medium 
RT   room temperature 
SA β-Gal  senescence-associated β-Galactosidase 
SASP   senescence-associated secretory phenotype 
SDF-1   stromal-derived-factor 1 
SIRPα   signal-regulatory protein α 
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slan   6-sulfo LacNAc 
slanMo  slan positive monocyte 
SLO   secondary lymphoid organs 
ssRNA   single stranded RNA 
STAT1   Signal transducer and activator of transcription 1 
T reg   T regulatory cell 
TAM   tumor-associated macrophage 
TCR   T cell receptor 
TGF-β   transforming growth factor beta 
Th   T helper 
TIGIT   T cell immunoreceptor with Ig and ITIM domains 
TLR     Toll-like receptor 
TMB   3,3´,5,5´-Tetramethylbenzidine 
TME   tumor microenvironment 
TNF-α   tumor necrosis factor-alpha 
TRAIL   TNF-related apoptosis-inducing ligand 
TT    Tetanus toxoid 
ULBP   UL16 binding protein 
VCAM1  vascular cell-adhesion molecule 1 
VEGF   vascular endothelial growth factor 
VLA4   very late antigen 4 
WB   Western Blot 
β2m   β2-Microglobulin 
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